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Abstract 
Understanding HIV transmission mechanisms is essential for the design and development of an 
efficacious, broadly acting vaccine that targets features common to transmitted viruses. However, 
there is a lack of consensus amongst current HIV studies characterising transmitted founders (TFs). 
When investigating the methods employed across studies, it becomes clear that methodologies are 
highly variable and thus, could be impacting research outcomes. This study therefore aimed to 
determine whether Envelope (Env) expression and processing affects function and whether cell type 
and/or expression system were responsible for these differences. Our data suggest that even though 
we did not observe differential expression of recombinant Env clones across cell types, when 
pseudovirus and infectious molecular clone (IMC) backbones were introduced, expression of Env 
decreased. We also found differences in processing in the form of cleavage, N-glycosylation and 
incorporation of Env across cell types. We conclude from this that methods used to study Env 
characteristics are highly sensitive to cell type and HIV backbone which suggests that a more 
standardised system is required to make meaningful comparisons between studies. The results of our 
functional Env analysis revealed high variation depending on the methodology used. We found that 
entry of TZM-bl cells by pseudovirus (PSV) is dependent on the cell line used to produce the viral 
particles. Unfortunately, due to low IMC titre, we had to expand the virus in PBMCs, negating the 
effect that cell type might have had on IMC expression. We could thus not directly compare PSVs to 
IMCs. However, PSV and IMC entry as well as IMC replication in PBMCs suggested that CHO cells were 
not suitable for robust viral production and better suited for recombinant Env expression. Overall, the 
findings in this project support previous findings that PSVs and IMCs are not directly comparable due 
to multiple factors that influence Env expression and virus production. We suggest that researchers 
who focus on HIV functional analysis, particularly Env, with the end-point of informing vaccine design, 
need regulated methods across laboratories, similar to the way that neutralisation assays were 
standardised.  
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Chapter 1 
Literature review 
1. 1 Introduction  
The Envelope (Env) of HIV-1 is first synthesized as a glycoprotein, gp160 which is then cleaved into 
gp120 and gp41 8. The two glycoproteins associate and form a trimer of gp120-gp41 heterodimers 9. 
The gp120 subunit binds sequentially to CD4 and CCR5 receptors on the surface of T cells while the 
membrane-bound gp41 mediates fusion between the viral and host membranes enabling viral entry 
and replication in the host cell 8. As this step mediates the first contact with host cells, inhibition of 
Env-host interactions would prevent transmission and is thus an important target in the development 
of novel drugs and vaccines against HIV. 
To understand the mechanism of HIV transmission, PSVs or IMCs are generated to mimic in vivo HIV-
1 infection. However, previous studies on HIV-1 transmission have reported conflicting results, which 
could, in part, be due to differences between PSV and IMC methodologies 10-12. This review aims to 
discuss studies that have utilised PSV and IMC assay systems, within the context of HIV-1 transmission, 
to evaluate the relevance of these findings to vaccine development.  
1.2  HIV diversity 
High HIV diversity is a major challenge to the development of an effective vaccine noting that Env from 
different subtypes can vary by 30 % 13. HIV is grouped in to two genetically distinct types, type 1 (HIV-
1) and type 2 (HIV-2) 14, with the former subdivided into four groups (M, major; O, outlier; N, non-M, 
non- O; and P) and Group M further divided onto 9 subtypes (A1, A2, B, C, D, F1, G, H, J, and K) plus 
43 circulating recombinant forms (CRFs) (see Los Alamos National Lab (LANL)-database; 
http://www.hiv.lanl.gov). CRFs are recombinant viruses that arise due to co-infection of two or more 
subtypes and circulate within a certain region. Unique recombinant viruses on the other hand have 
unique breakpoints and are poorly transmitted in the population 15,16. HIV-1 subtype B is the dominant 
variant in North America, Western Europe, and Australia, whereas subtype C viruses are found mainly 
in Southern Africa and India. Subtype C accounts for more than half of all HIV infections worldwide 1,17  
(Figure 1.1), emphasising the need for further research on this subtype as a vaccine raised against 
subtype B might not protect against other subtypes. 
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1.3  HIV-1 immune response 
HIV-1 infection can be divided into three stages – acute, early and chronic (Figure 1.2) 4. During early 
stages of infection, neutralisation antibodies to HIV-1 are not produced, leading to chronic infection 
11. HIV-1 is known to elicit humoral and cytotoxic T-lymphocyte (CTL) immune responses. A robust CTL 
response is essential to control viral infections 18. In the case of HIV-1, long-term non-progressors have 
higher amounts of HIV-1-specific CTL precursor cells compared to those who have progressed to AIDS 
18. The increased level of CTL response is correlated with a decrease in plasma viremia. These results 
indicate that CTL response to HIV-1 infection is essential for controlling virus replication and is 
therefore a potentially important aspect for vaccine development 19,20. Acute and early HIV-1 infection 
is defined by the presence of specific viral markers and antibodies in the blood 21. The first antibody 
response to HIV-1 infection is a non-neutralising response and the first neutralising response can only 
be detected three months after infection 21. Acute HIV-1 infection leads to the reduction of CD4+ T 
lymphocytes in lymphoid tissues, which cannot be replaced once destroyed. This is a possible 
explanation for the weak CD4+ T cell response to acute infection 21. Broadly neutralising antibodies 
(bnAbs) could be the key to an effective vaccine against HIV-1 22,23 but the generation thereof has 
proven to be very complex. The high variation of Env present in the early infection virus population is 
likely the result of immune pressure exerted by nAbs (neutralising antibodies) 24. The pressure exerted 
by nAbs, which target Env, results in escape variants 24. A study by Wei, et al. 25, showed that escape 
variants presented with mutations that were linked to changes in N-glycosylation sites. Studying 
immune responses to HIV is of great importance as these studies will inform vaccine design.  
 
Figure 1.1:  HIV-1 subtypes and recombinants forms (RFs) circulate within specific regions globally 1,2. 
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1.4 HIV-1 replication 
HIV-1 infection begins with the attachment of Env to the CD4 receptor and co-receptors on the cell 
surface of helper-T cells, followed by fusion between viral and host cell membranes (Figure 1.3). Upon 
entry into the cell, the viral RNA and the content of the viral core are released into the host cell (Figure 
1.3). This is followed by reverse transcription of the viral RNA into a double-stranded DNA molecule 
by the enzyme, reverse transcriptase. This DNA molecule is transported to the nucleus where the viral 
DNA is integrated into the host’s genome. Upon activation of the LTR promoter, other viral proteins – 
Gag, Nef, Tat and Rev are produced 8. Once the viral proteins required for new virions are made, viral 
particles containing all of these necessary proteins are formed and the particles bud off from the host 
cell after acquiring new Env proteins (Figure 1.3). The Env proteins on the surface of the new viral 
particles are free to attach to other CD4+ cells to begin a new round of replication. 
 
 
 
 
Figure 1.2: Changes in viral load and CD4+ T cell counts over the course of HIV infection. HIV infection is characterised by 
an increase in viral load (red) during acute infection, with a decrease in CD4= T cell count (blue). The immune responses then 
reduce viral loads until viral setpoint and clinical latency which can last for many years before the onset of AIDS-related 
infections (reproduced from 4). 
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1.5  Envelope processing and function  
The production of functional Env proteins is reliant on the correct processing thereof, which consists 
of synthesis, trimerization, N-glycosylation and cleavage. Moreover, the interactions between gp120 
and gp41 with host and viral proteins are vital for proper functioning and processing. For example, the 
interaction between Gag and the cytoplasmic tail of gp41 is crucial for incorporation of Env as it 
mediates the formation of Gag-Env particles 26. N-glycosylation of Env is a crucial step of processing in 
which N-linked glycans are enzymatically added to the protein at specific amino acid motifs, called 
potential N-glycosylation sites (PNGS) 27,28. The addition of these glycans affect structure and can affect 
function of Env. Expression of Env also influences N-glycosylation as Bonomelli, et al. 29 showed that 
when Env is overexpressed, the N-glycosylation profile is altered. Another important step in Env 
processing is the cleavage of gp160 into gp120 and gp41. Cleavage is essential for Env functionality as 
only incorporated gp120-gp41 trimers allow for viral infection. The incorporation of uncleaved gp160 
into viral particles will render the virus non-infectious 30. The effect of processing, specifically cleavage 
and N-glycosylation, on Env function will be investigated in detail in this study.  
 
Figure 1.3: Overview of the replication cycle of HIV-1. 1) Contact and attachment of the HIV-1 virion with the host cell CD4 receptor. 2) 
Fusion of the viral and host cell membranes. 3) Release of the viral RNA and viral core into the host cell. 4) Reverse transcription of the viral 
RNA into viral DNA. 5) Formation of the preintegration complex (PIC) and import into the nucleus. 6) Integration of the PIC into the host 
DNA. 7) Transcription into the viral mRNA. 8) Export of the viral mRNA into the cytoplasm. 9) Translation into viral proteins. 10) Assembly of 
proteins into the viral genome. 11) Budding of the immature virion from surface if the host cell membrane. 12) Release of the immature 
viral particle. 13) Maturation of the viral particle. (6) 
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 1.5.1  Structure  
 
 
 
 
 
 
 
 
The glycoproteins gp120 and gp41 are non-covalently associated and form trimers of heterodimers 9 
on the surface of HIV-1 particles (Figure 1.4 A). The gp120 surface subunit is made up of variable (V1-
V5) and constant (C1-C5) regions demarcated by disulphide bonds 31,32. The C1 and C5 regions contain 
residues essential for gp41 binding while C4 has been implicated in membrane fusion 33. The V1-V5 
regions contain conserved PNGS that aid in shielding Env from immune recognition although V2 and 
V3 are also known targets for nAbs 33 34. V2 and V3 are important for membrane fusion and for 
determining HIV-1 tropism 33.  
Gp41 is comprised of a cytoplasmic tail, transmembrane region and a highly conserved hydrophobic 
membrane proximal external region, known as the MPER. The MPER is believed to be involved in 
trimer self-assembly, 35 whereas the C-terminal tail is essential for anchorage into the viral lipid 
membrane 35. Truncation of the C-terminus leads to a soluble form of the glycoprotein, termed gp140, 
due to its approximate molecular weight of 140 kDa 36,37.  
 1.5.2 Function  
The gp120 subunit is responsible for binding to the CD4 receptor and CCR5 co-receptors on the surface 
of macrophages and helper T cells 38 and to CD4 and CXCR4 on the surface of T cells 39 while gp41 
mediates the fusion of the viral membrane with the host cell membrane 40. Upon gp120 binding to 
CD4, a conformational change is induced which allows binding to co-receptors CCR5 or CXCR4 41. 
Binding to co-receptors brings about further conformational changes which ultimately result in the 
exposure of the hydrophobic fusion peptide of gp41 42. This then leads to further conformational 
changes which allow gp41 to form a six-helix bundle (Figure 1.4 B) that fuses the viral and host cell 
membranes together 42 for delivery of the vRNA to the host cell 40. 
Figure 1.4: A) Schematic diagram of the HIV-1 virion structure. Figure taken from: www.scistyle.com.B) Process of Env binding to CD4 
receptor and co-receptors followed by membrane fusion and formation of a six-helix bundle 3. 
A B 
19 
 
Gp41 has also been shown to play a role in the formation of syncytia 43. Initially viruses were 
designated as M-tropic and T-tropic depending on whether they infected macrophages or T cells, 
respectively 44. However, subsequent studies identified viruses as R5- and X4-tropic based on receptor 
binding and M- or T-tropic depending on the cell type infected 45. Transmitted founders (TFs) have 
been identified as R5-tropic and T-tropic as they bind to the CCR5 co-receptors on T cells 45. Given that 
gp120 and gp41 mediate the first interaction between the virus and the host cell, Env is thus a crucial 
element in HIV-1 transmission, infection and vaccine design. 
 1.5.3  Cleavage 
Like other retroviruses, the Env protein is synthesized as a polyprotein which is then proteolytically 
processed into the mature glycoprotein 46. Cleavage is carried out at a conserved tetrapeptide 
sequence, Arg-X-Arg/Lys-Arg, by host cell proteases 30,46. There are two potential cleavage sites 
located directly upstream of the gp41 N-terminus. When either of these cleavage sites were mutated 
on their own, cleavage still took place at the intact site but when both were mutated together, 
cleavage was completely abrogated 30. The uncleaved mutants were still transported efficiently to the 
cell surface however, the viruses containing these proteins were non-infectious 30. Although the 
viruses containing mutations at only one of the cleavage sites were still cleaved, they were inefficiently 
incorporated, thereby demonstrating that these two sites are crucial for generating fully infectious 
viruses 30. 
The cleavage of gp160 into gp120 and gp41 is essential for their respective functions. N-glycosylation 
of Env has also been shown to affect cleavage of the polyprotein into its subunits 47. Dash, et al. 47 
showed that when certain PNGS are mutated cleavage does not occur, resulting in non-functional Env 
proteins. Taken together, these results imply that incorrect processing of Env results in non-infectious 
virus particles. Incomplete processing of Env can have various effects on the resulting virus and 
consequently on immune responses. Crooks, et al. 48 found that HIV-1 virus-like particles (VLPs) carried 
a monomeric, uncleaved form of Env that appeared to bypass the normal protein maturation steps 48. 
Not only was the Env uncleaved and not trimerized, the N-glycosylation profile was also altered 
leading to changes in antibody recognition 48.  
 1.5.4. N-glycosylation 
Gp120 and gp41 are both highly N-glycosylated, have highly variable glycosylation patterns, with N-
glycans making up roughly half of the total mass of gp120.  Gp120 has a variable number and 
positioning of PNGS 28, while gp41 is less extensively glycosylated with most PNGS conserved across 
isolates 49. The extensive N-glycosylation of Env shields it from immune recognition however, it is not 
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Figure 1.5: Three major types of N-glycans. Envelope N-glycans can comprise of High mannose, hybrid and 
complex carbohydrates. Figure taken from: www.scistyle.com. 
yet understood how the variability in glycosylation affects antibody reactivity 28,50. Contrary to 
shielding Env, some N-glycans provide epitopes for bnAbs 22,50-52, further emphasising the importance 
of N-glycosylation patterns. Due to differences in N-glycosylation machinery, cell types differentially 
N-glycosylate Env 28 so that expression in one cell line can drastically affect N-glycan patterns and thus 
immunogenicity, posing a huge problem for vaccine design.  
 
 
 
 
 
 
 
 
 
In the endoplasmic reticulum (ER) N-linked glycans are attached co-translationally to the protein at 
specific amino acid motifs, N-X-S/T, called PNGS. N-glycans have a common trimannosyl core structure 
which is composed of pentasaccharides. They can further be classified into three different types based 
on their structure. The three types are referred to as high mannose, complex or hybrid (Figure 1.5). 
High mannose N-glycans have only mannose bound to the core, the complex type has more than two 
N-acetyl glucosamine residues (GlcNAc) with variable numbers of galactose and sialic acids and the 
hybrid form is a mixture of the complex and high mannose types 27. These structures are highly variable 
and their synthesis has been shown to be cell-specific 28. 
After mannosylation, gp160 trimerises and N-glycans are further modified to complex or hybrid 
carbohydrate structures in the Golgi, before cleavage into gp120 and gp41 and the incorporation of 
functional trimers into viral particles 52. 
It has been suggested that there is rapid turnover of Env at the plasma membrane due to endocytosis 
and shedding of gp120. Therefore, it has been suggested that approximately ten Env trimers are 
incorporated per virus 53. Increased expression of Env did not lead to increased infectivity, and it was 
thus hypothesised that low numbers of Env on the virion surface was an advantage to the virus as it 
limited recognition by the immune responses 54. 
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 1.5.4.1  N-glycosylation in various cell types  
Although PNGS are determined by the viral genome, the biosynthetic machinery of the host cell is 
responsible for the addition and composition of N-glycans. Therefore, N-glycan profiles are highly 
variable between isolates with some PNGS being unoccupied 28. When recombinant gp120 was 
produced in CHO and Dakiki cells, the molecular mass was revealed to be approximately 125 kDa while 
in HepG2 cells the mass was approximately 145 kDa. This difference could be explained by the 
differential ratio of high mannose relative to complex N-glycans. Gp120 produced by T cells and CHO 
cells were more heavily mannosylated than gp120 produced in HepG2 cells which had high levels of 
heterogeneous complex N-glycans 28.  
 Recombinant subtype C TF gp120 produced in Chinese hamster ovary (CHO) cells and human 
embryonic kidney (HEK293T) cells differed in that the former cell line produced more sialylated, 
fucosylated and phosphorylated N-glycans. There were also differences at specific PNGS where CHO 
cells added high mannose while HEK293T cells added more complex residues and vice versa 55.  
Interestingly the gp140 construct of the same TF Env used in the 2013 study had a similar N-
glycosylation profile as the gp120 monomers analysed in 2011, suggesting that gp140 and gp120 N-
glycosylation might be similar irrespective of the presence of additional gp41 sequence 56. 
Glycosylation of Env is essential to its folding in the ER, suggesting that expression in different cells 
will produce gp120 with variable function and structure. 
1.6 HIV-1 transmission 
Despite the genetic variation, and most likely phenotypic variation of the donor virus population, 
transmission and clinical infection of HIV-1 is as a result of a single variant, deemed the TF virus 57 58. 
If a single variant is usually selected, that TF virus is likely to carry a selective advantage over the rest 
of the variants 59. The high mutation rate of HIV-1 coupled with the selection pressure from the host’s 
immune system results in rapid evolution so that the viruses at chronic stages of infection are no 
longer similar to the TF. Characterisation of variants sampled at late stages of infection will thus, most 
likely, not represent the founder population. Single genome amplification (SGA) enabled the 
identification of the TF and a number of studies have focused on understanding how the phenotype 
of the TF contributes to HIV transmission 57,60. The research community rationalised that a TF-specific 
phenotype or transmission motif(s) would make ideal targets for vaccine design as these would be 
functionally constrained and thus conserved across the transmitted population.  
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 1.6.1  HIV-1 Transmitted founder selection mechanisms 
 1.6.1.1  R5 tropism 
Thus far, the only common feature of all TFs is that they are all R5-tropic which suggests that either 
some barrier prevents transmission via CXCR4 or that CCR5 receptors possess some selective 
advantage over CXCR4 61. This is evident in studies showing that those failing to express a functional 
copy of CCR5 are generally protected from HIV-1 infection even when a functional CXCR4 is present, 
thus demonstrating a strong positive selection towards CCR5. Deciphering the mechanism acting to 
prevent infection via CXCR4 or the mechanism acting to promote infection of CCR5+ cells is important 
for vaccine development 62. 
The V3 loop that interacts with CXCR4 has a higher level of exposed cationic charge compared to R5-
tropic gp120 which could lead to more interaction between CXCR4 and mucin and thus, more efficient 
clearance and impairment of infectivity 61. Furthermore, in the lower female genital tract (FGT), levels 
of CCR5 mRNA are up to ten fold higher than levels of CXCR4 suggesting that cells expressing CCR5 are 
more common in the FGT than those carrying CXCR4 cells 61. However, McClure, et al. 63 found 
conflicting evidence as FACS analysis showed that CXCR4 was increased on the cell surface in the FGT 
63. R5-tropic variants might have an advantage during penile transmission, because although the levels 
of CCR5 and CXCR4 are equivalent in the urethral tissue, Langerhans cells and CD4+ T cells express 
more CCR5. Another study reported that X4 viruses may be more sensitive to inactivation by proteins 
found in the vaginal mucus 64, however, this was refuted by Sun, et al. 65 who found that there was no 
difference in sensitivity of X4 and R5 variants to inactivation. 
Parker, et al. 66 reported that subtype B and C chronic control (CC) Envs were better able to utilise a 
maraviroc (MVC) (CCR5 antagonist)-bound CCR5, while Wilen, et al. 59 found no difference. The 
findings by Parker, et al. 66 suggest that CC Envs are more likely to infect cells in the presence of MVC 
which in turn implies that CC Envs are selected against during transmission, but selected for during 
chronic infection, due to their ability to utilise different conformations of CCR5. How this will provide 
a selective advantage during transmission is still unclear. 
Given that one single natural barrier cannot fully explain the strong selection of R5 tropic TFs, it is 
therefore possible that a combination of mechanisms act in concert to favour R5-tropic variants during 
transmission 62. 
 1.6.1.2 N-glycosylation in transmission  
Derdeyn, et al. 67, and Chohan, et al. 68 found that subtype C TFs tended to have shorter variable loops 
with fewer PNGS 68,69. The authors suggested TF Env were less N-glycosylated and that this might 
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provide a selective advantage. In contrast, Frost, et al. 70 investigated the variable loop length and 
number of PNGS in subtype B variants and found no difference between TF and Envs from variants 
during chronic stages of infection 70. It was suggested that subtype B and C TFs might have evolved 
along alternative paths resulting in different transmission motifs. When Go, et al. 56 compared the N-
glycosylation of HEK293T cell-derived recombinant TF and CC Envs from subtype C and subtype B, they 
found that the two TF Env’s N-glycosylation was more similar to each other than to the Envs from 
chronic stages of infection with the most marked difference being the abundance of complex sugars 
56. This suggests that there is a difference N-glycosylation between TF and CC Envs, although the 
reason remains unknown. 
 1.6.1.3  Trans-infection of HIV-1 by dendritic cells 
Although a controversial topic, it has been suggested that dendritic cells (DCs) are potentially involved 
in the selection of TFs based on their Env N-glycosylation. It has been shown that DCs are responsible 
for the trans-infection of T cells during HIV transmission where DCs capture HIV in the FGT, migrate to 
the lymphoid nodes where CD4+ T cells become infected, fuelling rapid HIV replication. DCs express a 
C-type lectin called DC-SIGN (dendritic cell specific ICAM3-grabbing non-integrin) that binds to gp120 
high mannose residues 71. Endoglycosidase H (Endo H) treatment abrogated gp120 binding to DCs and 
DC-SIGN+ cells 72. Furthermore, by producing gp120 in different cell lines, it was demonstrated that 
DC-SIGN did not bind to macrophage-generated gp120 due to its high complex sugar glycosylation 73. 
This suggests that Env N-glycosylation might be important for HIV transmission. 74. Parrish, et al. 75 
suggested that TF viruses were more susceptible to being captured by DC-SIGN and thus more easily 
transferred to CD4+ T cells 75. However, when investigating the susceptibility of pseudotyped TF viruses 
and CC viruses to being captured by DC-SIGN, Wilen, et al. 59 failed to find any significant differences 
(Table 1.1).  
 1.6.1.4  The role of α4β7 integrin in HIV transmission 
Dissemination of the virus into the gut-associated lymphoid tissue (GALT) results in rapid depletion of 
CD4+ cells, a contributing factor to the loss of immune responses during progression to AIDS-defining 
illness. The integrin, alpha-4-beta-7 (α4β7), is highly expressed on CD4+ T cells of the FGT 76 and gut 
that preferentially express the CCR5 co-receptor 77. It has been suggested that α4β7 is responsible for 
the dissemination of HIV to the GALT by transporting infected T cells. The homing integrin binds to the 
V2 loop of gp120 via a binding motif and when the site was mutated the efficiency at which the virus 
replicated decreased 78. The reactivity of α4β7 increased when PNGS were deleted in the V1-V2 loop 
and it was proposed that TF variants with fewer N-glycans in this region might bind α4β7 with higher 
affinity and thus have an advantage that facilitates their transmission 79. CD4, CCR5 and α4β7 form 
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complexes on the surface of T cells 77 and therefore, binding to α4β7 might promote interactions with 
CD4 and CCR5, enhancing HIV infection of host cells 78. More recently it was shown that gp120-α4β7 
interaction is involved in synapse formation and cell-cell transfer of HIV 78.  Parrish, et al. 80 however, 
reported that blocking the α4β7 receptor with Act-1 (an mAb against α4β7) had no effect on viral 
infectivity. The same research group also showed that TFs did not bind α4β7, CD4 or CCR5 better than 
variants from chronic stages of infection, suggesting that the interaction between gp120 and α4β7 was 
not essential for transmission 80. Therefore, it has yet to be proven that α4β7 is involved in HIV 
transmission due to Env N-glycans. 
 1.6.1.5 Neutralisation sensitivity  
One early study suggested that variants circulating soon after transmission would be more sensitive 
to neutralisation 69. The premise of their hypothesis was that escape from neutralisation during 
chronic infection came with a fitness cost and thus, most variants at later time points had low 
infectivity. Therefore, the variants transmitted had not escaped immune responses and had high viral 
fitness. In support of this suggestion,  Wilen, et al. 59 found that the clade B TF Envs exhibited increased 
sensitivity to mAbs b12 and VRC01 and clade B HIV Ig. The increased sensitivity was not seen with 
bnAbs PG9 and PG16 that recognise Env N-glycans. Go, et al. 55 showed that TF gp120, despite having 
differences in N-glycans, did not differ in antigenicity when treated with a range of antibodies: C1 
(A32), conformational V2 (697D, 2158), CD4 binding site (VRC01), and the carbohydrate binding bnAb 
2G12. Furthermore, PG9, PG16, and CH01 did not even bind to gp120 55. Studies, thus far, have not 
shown consistent findings on the antigenicity of TF Env which has direct implications for vaccine 
design. 
 1.6.1.6 Transmission motifs 
When Env sequences representing TF and CC were compared, two transmission motifs were 
identified: His12 in the signal peptide and a PNGS at position 413 within gp120 81. Asmal, et al. 82 
suggested that these motifs provided TFs with the advantage of increased Env processing and 
incorporation into HIV particles thus enhancing viral replication 82. On the other hand, Wilen, et al. 59 
suggested that the transmission of HIV-1 requires only a fit R5-tropic virus and that no single genetic 
or phenotypic characteristic enabled transmission. They concluded that any small changes in Env 
function that increased viral fitness could provide the necessary selective advantage for infection via 
CCR5 59. When Parrish, et al. 83 compared the characteristics of TF and CC Envs they suggested that TF 
viruses have higher levels of incorporated Env and are more infectious than CC viruses 83.  It is possible 
that any one of these factors - binding DC-SIGN, binding α4β7, incorporation, antigenicity etc -might 
randomly provide an advantage to transmitted variants by enhancing viral fitness and that not all TFs 
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have the same advantageous phenotype. This might explain the lack of consensus between studies 
with regard to the selection mechanism of TFs.  However, it is also possible that the lack of 
standardised methodology to study HIV transmission might have affected the outcome of the 
experiments, so we cannot compare one finding to another (Table 1.1).  
 
 
 
1.7  Methodology used to characterise transmitted founders 
 1.7.1  Cell lines 
According to tables 1.1 and 1.2, a number of different cell lines have been used to investigate TF 
characteristics, although HEK293T cells and their derivatives are the most common. Vaccine 
production on the other hand, usually utilises CHO cells. The selection of cells will be affected by the 
expression of HIV restriction factors such as APOBEC3G, TRIM5alpha, and tetherin 84. PBMCs have 
been shown to express all these factors and replication of HIV is dependent on the expression of 
viral proteins that negate restriction 85.  These viral proteins include Vif, Nef, Vpu, and Vpr 86. Vpu 
overcomes the effect of tetherin by sequestering the restriction factor in the trans golgi network. 
Cell lines are termed “restrictive or Vpu-responsive cells” if they require Vpu for HIV infection such 
as CHO, HeLa, T cells (Jurkat, CEM) and primary T lymphocytes. HEK293T, HOS and HR1080 cells on 
the other hand are termed “permissive or Vpu-unresponsive” as they do not produce tetherin 87. 
Paper PSVs/IMCs Env clone origin Number 
of clones 
HIV backbone Host cell line 
Parker 
et al.  
PSVs and 
chimeric 
IMCs 
Clade B/C 40 pNL43-⌬Env-
vpr⫹-luc⫹ or 
pNL43-⌬Env-
vpr⫹-eGFP 
293T17, 293T-derived 
Affinofile, 
NP2/CD4/CCR5, 
NP2/CD4/CXCR4 & 
U87/CD4 
Parrish 
et al.  
Full-length 
IMCs 
Clade B/C TF; n=27 
CC; n=14 
NA 293T 
Wilen 
et al. 
PSVs Clade B 
T/F Envs were selected from 
single-variant transmission. CC 
Envs amplified from 14-83 
months post infection. 
Southeastern and Northwestern 
US. 
TF; n=24 
CC; n=17 
pNL43-⌬Env-
vpr⫹-luc⫹ or 
pNL43-⌬Env-
vpr⫹-eGFP 
293T17, NP2 cells 
Table 1.1: Variation in study methodology that compared IMCs with PSVs. 
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Although CHO and HeLa cells require the presence of Vpu to produce virus particles they are used 
extensively in HIV-1 research and we thus included them in this study. 
 1.7.2 Purified recombinant Envelope 
A number of studies have looked at N-glycosylation and antigenicity using purified recombinant gp120 
or gp140 55,56,78,88. This involves the over expression of recombinant proteins in cell lines, usually CHO 
and HEK293T cells, and purification using N.galanthus lectin affinity chromatography. Soluble forms 
of Env, gp140 and gp120, are used as these are secreted directly into the culture supernatant, 
circumventing the plasma membrane and making purification easier. It has been raised that 
monomeric Env does not represent the trimeric form and that using recombinant proteins might lead 
to results that do not represent native protein found in vivo 89,90. This problem has been circumvented 
by the use of disulphide linked trimers 89. Purifying Env trimers from PSVs, IMCS or primary isolates 
have a number of challenges, most notably the low levels of Env incorporation. Therefore, phenotypic 
characterisation of Env has utilised whole virus in the form of PSVs and IMCs and not purified protein. 
As most studies on TF phenotype have utilised PSVs and chimeric IMCs, this review will focus on these 
methods. 
 1.7.3  Pseudoviruses and infectious molecular clones  
PSVs and IMCs are two common systems used to investigate and characterise HIV. PSVs are produced 
by expressing the HIV genome, with a deletion in the Env gene, using an exogenous promoter such as 
that of the cytomegalovirus (CMV) to ensure high expression of all viral proteins or the LTR, to 
maintain physiological levels of expression. The env gene is cloned into an expression vector under 
the control of a constitutive promoter. When vectors are co-transfected into cell lines, PSVs are 
produced carrying the HIV-1 RNA genome without a functional env. These PSVs are replication-
incompetent and are capable of only a single round of infection 12. PSVs are commonly used to 
characterise and compare Env function as a common HIV genome can be pseudotyped with a number 
of different Env variants. A reporter cell line, such as TZM-bl cells, is then used to measure the ability 
of the Env clones to mediate efficient entry. 
Infectious molecular clones are used to study viral replication. These clones carry the full proviral 
genome of HIV. Transcription is driven by the LTR which means that mRNA splicing and rate of 
production are the same as native virions 12. Usually, Envs are cloned into a common backbone to 
generate chimeric IMCs in order to compare the impact of different Env clones on viral replication. 
Contrary to PSVs, IMCs are fully infectious. However, when Provine, et al. 12 compared Env cleavage 
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and incorporation between PSVs and IMCs, they found that IMCs exhibited significantly higher levels 
of cleavage and incorporation but showed no significant differences in neutralisation sensitivity.  
 
 1.7.4  Comparison between PSV and IMC results  
In order to directly compare the results obtained from the PSV and IMC systems, Provine, et al. 12 
utilised the 6 matched PSVs and chimeric IMCs. They observed four factors that are known to influence 
HIV-1 function and infection; cleavage of Env into gp120 and gp41, the amount of Env incorporated 
into the virion, viral infectivity and sensitivity to the inhibitors that target different steps in viral entry. 
As determined by p24 levels, PSVs and IMCs produced similar amounts of virions. By using the relative 
amounts of gp160 and gp120, Provine, et al. 12 calculated that there were significant differences in 
Env incorporation for 3 out of the 6 pairs tested, suggesting that the assays influence experimental 
outcome in a clone-specific manner. Across all 6 pairs, most showed less incorporation in PSVs. The 
gp160 and gp120 levels were also used to determine the percentage cleavage. This showed that IMCs 
always had a higher percentage gp160 cleavage than did PSVs 12. 
To determine whether these differences had any biological significance, each pair was assayed for 
neutralisation and infectivity. Differences were observed in infectivity in all 6 pairs. However, there 
was no consensus as to whether IMCs or PSVs were more infectious. Neither incorporation nor 
cleavage alone could explain the differences in infectivity 12.  
To test the sensitivity to neutralisation, two matched pairs with marked differences in cleavage, 
incorporation and infectivity were chosen. These pairs were exposed to antibodies and inhibitors that 
targeted different stages of viral fusion 12. The results showed that neutralisation/inhibition sensitivity 
to mAbs was similar for both pairs. In another study conducted by Louder, et al. 10, identical Env genes 
were inserted into both PSVs and IMCs. When compared, the PSVs showed similar neutralisation 
sensitivities to IMCs for a number of antibodies. However, after one passage in HEK293T cells, IMCs 
differed in neutralisation sensitivity in comparison to PSVs. This appears to be a host cell effect, as no 
genetic changes in Env were observed. Long-term culture of HIV-1 may cause genetic changes which 
can result in changes in neutralisation, incorporation and infectivity 10. This has major implications on 
vaccination research.  
In another study done by Miglietta, et al. 11, three PSVs were compared to three TF IMCs with almost 
identical Env sequences (Table 2). The PSVs and IMCs were produced in HEK293T cells to eliminate 
the effect of host cell on neutralisation sensitivity. They also used the TZM-bl assay as a standardised 
method to eliminate any other sources of variability. Their results showed that PSVs were as sensitive 
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to neutralisation as IMCs but that IMCs had higher IC50s. The difference in IC50 could not be fully 
explained by Env sequence, nor by the use of PSVs versus IMCs. This result was corroborated by 
Provine, et al. 12.  
Any differences in neutralisation sensitivity may be explained by the method of Env expression which 
differs between PSVs and IMCs. In PSVs the Env gene is expressed on a separate plasmid, while in IMCs 
the full proviral genome is usually expressed by the LTR 11. When using PSVs, it is possible that certain 
properties of the Env protein are altered due to Env being expressed by a separate plasmid. Another 
important factor that could influence neutralisation sensitivity is the Env:backbone ratio 12. Varying 
this ratio resulted in PSVs with different levels of Env cleavage, as well as different levels of gp120 
expressed on the cell surface. These alterations have been shown to affect the infectivity and possibly 
antibody reactivity, which has implications for vaccine development 11.  
Based on these results, the virions produced by PSVs and IMCs are not identical. They differ in Env 
processing, such that IMCs exhibit higher levels of Env processing. This is demonstrated by cleavage 
of gp160 into gp120 and gp41. Despite the difference in Env processing, no differences were observed 
in neutralisation sensitivity and incorporation was isolate-dependent. Therefore, both systems might 
be acceptable when the differences in processing and cleavage of Env are considered in interpreting 
neutralisation assays. Overall these findings suggest that when comparing the PSV and IMC systems, 
great care must be taken to standardise the two methods.  
 
Paper Env clone origin Number of 
clones 
HIV 
backbone 
Host cell 
line 
Louder et 
al.  
Full-length env genes of HIV-1 BL01 and BR07 were 
cloned from blood and brain tissue.  
2 pairs pNL4-3env 293T and 
PBMC 
Provine et 
al.  
Maternal primary isolates, clade A 6 pairs Q23⌬env 293T 
 
 
 
 
 
 
Miglietta et 
al. 
Clade B, from sexually acquired, acute/early infections 11 (5 PSVs, 6 
IMCs) 
pSG3Δenv 293T 
 
1.8 Vaccine development 
Due to variation in findings of Env phenotype between studies, we next discuss the efficacy of vaccines 
within the context of methodology employed to produce the immunogen. One of the reasons for the 
Table 1.2: Variation in study methodology that compared IMCs with PSVs. 
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identification of a phenotype common to all TFs was that these motifs could be targeted during the 
rational design of vaccines. Generating an immune response specifically against TFs might prevent 
infection. However, in the absence of this information, immunogen design has relied on a shotgun 
approach where a number of methods and Envs have been utilised. Effective vaccines require virus-
specific CD8+ T cells as well as neutralisation antibodies 91. A number of different strategies have been 
employed over the years including DNA and protein-based vaccines 92. The AIDSVAX B/E is a vaccine 
against HIV/AIDS that is based on the Env protein gp120 92. After clinical trials by Gilbert, et al. 93 and 
Pitisuttithum, et al. 94 this vaccine was shown to be ineffective in protection against HIV. Thus, a new 
combination method was devised. The combination of AIDSVAX B/E with ALVAC canarypox vaccine 
led to the ALVAC-HIV/AIDSVAX B/E vaccine 92. This vaccine presented a 31 % protection against HIV-1 
infection and is the first to have demonstrated any level of efficacy. Future vaccines may be able to 
draw from the basis of the ALVAC-HIV/AIDSVAX B/E vaccine in order to improve the efficacy in 
prevention of HIV acquisition (Table 3). 
 
Name (Year) Country Type Result 
AIDSVAX B/B and 
AIDSVAX B/E 
(2002) 
Canada, USA, 
Netherlands and 
Puerto Rico 
recombinant gp120 surface proteins from different 
HIV-1 strains 
No protection 
STEP (2007) North America/ 
Australia 
adenovirus with synthetically produced HIV genes: 
gag, pol and nef 
Increased 
infection by 
48% 
RV144 (2009) Thailand Canary pox vector containing genetically engineered 
Env, gag and pol. Boost was composed of genetically 
engineered gp120 
Lowered 
infection by 
31% 
 
In the study done by Miglietta, et al. 11 as previously described, a number of antibodies were tested 
against PSVs and IMCs. This showed that no single antibody was able to neutralise all isolates whether 
PSVs or IMCs. Based on the results discussed, it is probable that when using methods that rely on 
293T-derived viruses, the potency of the antibodies being tested is overestimated 95. This would result 
in ineffective vaccines. Furthermore, the fact that no single antibody is able to neutralise the virus 
completely suggests that combinations of current vaccines, much like the ALVAC-HIV/AIDSVAX B/E 
vaccine described above, might prove to be the best way to develop a highly effective vaccine.  
Alternatively, we still have hope that identifying a phenotype common to all TFs might provide the 
direction needed to design an efficacious vaccine. 
 
Table 1.3: Summary of vaccine trials, outcomes and approaches used to date. 
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1.9 Conclusion  
Rational vaccine design depends on identifying features of HIV that, when targeted by the immune 
response, elicits a robust CTL and/or humoral response.  These features should be common to the 
majority of circulating isolates so that immune responses are broadly neutralising.  The discovery of 
TFs led to a number of studies that identified transmission motifs using a number of different 
approaches. These included PSVs, IMCs, and purified protein produced under different conditions. 
However, the structure and function of Env, the main target for vaccine design, was shown to vary 
depending on whether produced as PSV or IMC. This has important ramifications for, not only vaccine 
design, but also strategies employed to understand HIV-1 transmission. The accuracy of research 
findings is only as strong as the method used and without careful consideration, and standardisation 
of assays, we run the risk of testing vaccine candidates that will not protect against HIV-1 infection in 
highly vulnerable populations.  However, if selection of TFs is not due to a common feature, then a 
multi-pronged approach will be required where rational design of vaccines is coupled to random 
selection of variants and epitopes that prove to be highly immunogenic using cohort studies.  
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1. 10 Aim  
Understand how experimental methodology might have contributed to inconsistent findings related 
to the role of Env in HIV-1 transmission  
1.11 Objectives  
1.  Determine whether the expression, cleavage and incorporation of different Env clones into 
viral particles are influenced by the cell line used to produce pseudovirus and infectious molecular 
clones with different HIV backbones.  
2. Understand how entry of TZM-bl cells and replication kinetics of infectious molecular clones 
in PBMCs are affected by the cell line used to produce the infectious molecular clones with different 
HIV backbones. 
3.  Compare entry of TZM-bl cells with infectious molecular clones to that of matched 
pseudovirus to identify whether cell line, Env clone and/or backbone is a factor that contributes to 
potential differences in outcome of the two assays 
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Chapter 2 
Methods and materials 
 
2.1 Transforming E. coli  
Plasmid DNA was added to competent E. coli JM109 cells. The volume of DNA used was 1/10th the 
volume of the cells used. The DNA and cells were allowed to bind on ice for 25 – 30 minutes and 
subsequently heat shocked at 42 °C for 45 seconds and placed on ice again for 2 minutes. Luria broth 
(LB) (1% tryptone, 0.5% yeast extract, 1% NaCl in distilled water) was added up to 1 ml and the culture 
was allowed to grow at 37 °C, with shaking for 1 hour. After 1 hour, the cells were pelleted by 
centrifugation at 5 000 rpm for 5 minutes. The supernatant was removed, the pellet was resuspended 
in the remaining supernatant and then spread onto Luria agar (LA) (LB, 1.5% w/v agar and 100 μg/mL 
carbenicillin disodium salt) plates which were incubated at 37 °C overnight.  
 
2.2 Bacterial cultures 
LB was prepared in 5 ml and 50 ml aliquots. Plasmid glycerol stocks were used to inoculate LB 
supplemented with carbenicillin (Sigma) (100 g/ml). Starter cultures (5 ml) were grown at 30 °C for 
approximately 17 hours, with shaking. The starter cultures were then transferred to 50 ml LB, 
supplemented with carbenicillin (100 g/ml) and the same procedure was followed. 
 
 2.2.1 Plasmid DNA extraction 
DNA was extracted from 50 ml cultures using a Midiprep Kit (Promega) or the Plasmid DNA Purification 
kit (Qiagen) according to the manufacturer’s specifications. DNA was then stored at -20 °C until 
required. 
 
2.3 Tissue culture  
All cell lines (HEK293T, HeLa, CHO-K1 and TZM-bl cells) were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) which was supplemented with 10% Fetal Bovine Serum (FBS) and 1 U/ml penicillin 
and 1 µg/ml streptomycin. Cells were incubated at 37 °C and 5% CO2 in a water-jacket incubator.  
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 2.3.1 Transient transfections  
For each cell line, cells were plated at a density of 2x106 cells per well in a 6-well plate, in a total volume 
of 2 ml full DMEM. Cells were incubated overnight to allow growth to reach approximately 40-60% 
confluency.  
 2.3.1.1 Transfection of HEK293T cells 
Transfection mixes were made in 400 µl serum-free DMEM with Polyethylenimine (PEI) and plasmid 
DNA in a ratio of 3:1, PEI: DNA. pGL4-luc at a concentration of 0.5 µg was added as a measure of 
transfection efficiency. Transfection mixes were vortexed for 15 seconds and incubated at room 
temperature for 10 minutes to allow formation of complexes. Thereafter, growth medium was 
removed from the 6-well plate, replaced with 1.5 ml fresh medium and transfection mixes were added 
in a drop-wise fashion. Cells were incubated at 37 °C for six hours before medium was removed and 
replaced with 2 ml fresh medium, 1 ml for gp140 samples, and then incubated for a further 48 hours 
before cell lysis. 
 2.3.1.2 Transfection of HeLa and CHO cells 
Transfection mixes were made in 200 µl serum-free DMEM with Genecellin transfection reagent 
(Celtic) and plasmid DNA in a ratio of 3:1, Genecellin: DNA. As mentioned in section 2.3.1.1, 0.5 µg of 
pGL4-luc was added as a measure of transfection efficiency. Transfection mixes were vortexed for 3 
seconds and incubated at room temperature for 15 minutes. DMEM was removed from each of the 
wells in the 6-well transfection plate and replaced with 2 ml fresh DMEM. Transfection mixes were 
added in a drop-wise fashion and then incubated at 37 °C for 48 hours before cell lysis. 
 
 2.3.2 Endoglycosidase treatments 
One ml of medium was harvested from the wells of the gp140 and pcDNA transfections and placed 
into 2 ml Eppendorf tubes. One ml of MES buffer (pH 6: 20 mM MES monohydrate, 130mM NaCl, 
10mM CaCl2) and 30 µl of Galanthus nivalis beads was added to the medium and the mixtures were 
incubated at 4°C overnight, with rolling. The following day, the 2 ml tubes were centrifuged at 14 000 
rpm for 3 minutes after which the supernatant was discarded without disturbing the pelleted beads. 
The beads were washed with 1 ml of cold phosphate buffered saline (PBS), supplemented with Ca2+ 
and Mg2+, by centrifugation at 14 000 rpm for 3 minutes. The PBS was removed without disturbing the 
beads. This was repeated thrice. The pelleted beads were resuspended in 300 µl of PBS (Ca2+, Mg2+) 
and divided equally into three 1.5 ml eppendorfs labelled “untreated”, “Endo-H” and “PNGase F”. The 
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tubes were centrifuged at 14 000 rpm for 3 minutes and the supernatant was carefully removed. To 
the three tubes, 9 µl of dH2O and 1 µl 10x glycoprotein denaturing buffer (NEB) was added. The tubes 
were then boiled at 90°C for 10 minutes. To the “untreated” samples, 5 µl of dH2O, 2 µl of 10Xx buffer 
G7 (NEB) and 2 µl 10% NP40 was added. To the “Endo H” tube, 7 µl of dH2O, 2 µl of 10x buffer G5 and 
1 µl (1:3) Endo H was added. To the “PNGase F” sample, 5 µl of dH2O, 2 µl of 10x buffer G7, 2 µl of 
10% NP40 and 1 µl (1:3) PNGase F was added. All tubes were incubated at 37 °C overnight. The 
reactions were stopped by adding 5 µl of loading dye and boiling for 10 minutes at 90 °C. The total 
volume of each tube was loaded to an SDS-PAGE gel (see section 2.3.6 (for method)) for visualisation 
of proteins. 
 
 2.3.3 Cell lysis 
After 48 hours of incubation, DMEM was removed and 300 µl of RIPA buffer (10mM Tris, pH 7.2, 2mM 
EDTA, pH 8.0, 150mM NaCl2, 1% Triton X-100 (Sigma) and 0.1% phenylmethylsulfonyl fluoride (PMSF)) 
was added to each well. The 6-well plate was placed on ice for 5 minutes, during cell lysis. Lysates 
were collected in cold 1.5 ml Eppendorf tubes and left to lyse for a further 5 minutes on ice, then 
centrifuged at 4°C, at 14 000 rpm for three minutes. Cell debris was pelleted and the supernatants 
were transferred to fresh Eppendorf tubes. The samples were then stored at -20 °C until protein 
quantification and Western blot (see section 2.3.7) analysis. 
 
 2.3.4 Bradford assay 
Proteins in lysates were quantified using a Bradford assay. Bovine Serum Albumin (BSA) was serially 
diluted in RIPA buffer (1:10) to generate a standard curve which was used to quantify the unknown 
protein concentrations of the cell lysates. The 96-well plates were read at 595 nm using the Gen5 plate 
reader. 
 
 2.3.5 Transfection efficiencies 
To measure transfection efficiencies, 30 µl of lysates was mixed with 30 µl of BrightGlo (Promega). 
Luminescence was measured with a luminometer (Glomax 96 microplate luminometer) and relative 
light units (RLU) values were used to quantify entry of pGL4-luc into cells (a measure of transfection 
efficiency). 
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 2.3.6 SDS-PAGE 
An amount of 100 µg protein was added to protein loading buffer (1% SDS, 4% glycerol, 1% β-
mercaptoethanol and 0.01% bromophenol blue) and then boiled at 100°C for 10 minutes in order to 
denature the proteins. The protein samples were loaded into a 5% acrylamide stacking gel and a 10% 
acrylamide resolving gel and run in running buffer (25mM Tris, 190 mM glycine, 0.1 % SDS) under 0.2 
mA for small gels and 0.6 mA for large gels. Proteins were transferred to pre-wet polyvinylidene 
difluoride (PVDF) membranes (Bio-Rad) using the Bio-Rad Mini Trans-Blot® Cell according to the 
manufacturer’s instructions.  
 2.3.7 Western blots 
After protein transfer, PVDF membranes were incubated at 4°C overnight in blocking buffer (5% fat 
free skim milk, 0.5% Tween-20 in tris buffered saline (TBS)). These membranes were cut into segments 
in order to separate the low molecular weight proteins from the high molecular weight proteins. Each 
membrane was incubated at room temperature for one hour, with shaking, in the corresponding 
primary antibodies. The low molecular weight membranes were incubated in mouse anti-β-actin 
antibody while the high molecular weight membranes were incubated in sheep anti-gp120 antiserum 
(ARP Cat #288). Membranes were washed thrice with TBS-T (50 mM Tris, 150 mM NaCl, pH 7.5, 0.5 % 
Tween-20), in 15 minute intervals, with shaking at room temperature. Secondary antibodies were 
added to their respective membranes and incubated for one hour at room temperature, with shaking. 
Low molecular weight membranes were incubated in horse-radish peroxidase conjugated goat anti-
sheep IgG and high molecular weight membranes were incubated in horse-radish peroxidase 
conjugated goat anti-mouse IgG. Once again, membranes were washed thrice in TBS-T in 15 minute 
intervals. A fourth wash was done in TBS. In order to visualise the proteins on autoradiographic film 
(Santa Cruz Biotechnology®), Lumino Glo® substrate kit was added to each membrane.  
 2.3.8  Pseudovirus production 
 2.3.8.1  Pseudovirus production in HEK293T cells 
HEK293T cells were plated at a density of 2 x 106 cells per ml in 2 ml in a 6-well plate, then left to 
incubate overnight at 37°C. Cells were ~40 – 60 % confluent prior to transfection. Transfection 
complexes were generated by adding DNA and PEI in a 3:1 ratio (2.5 µg gp160 + 5 µg of pSG3Δenv + 
22.5 µl PEI), to 400 µl of serum-free medium. Transfection mixes were vortexed for 15 seconds and 
incubated at room temperature for 10 minutes. Medium was removed from each well and replaced 
with 1.5 ml of fresh medium before adding complexes in a drop-wise fashion. Cells were incubated for 
48 hours before harvesting PSVs. 2 ml of medium was collected from each well and placed into 2 ml 
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syringes. Culture medium was then filtered into 15 ml tubes through 0.2 µm filters. 200 µl of FBS was 
added to each sample to obtain a final concentration of 10 % FBS. The medium was mixed thoroughly 
and aliquoted into Eppendorfs (50 µl) for quantification via p24 ELISA and cryovials for long-term 
storage. All samples were stored at -80 °C. 
 2.3.8.2  Pseudovirus production in HeLa cells 
HeLa cells were seeded and incubated in the same way as described above for HEK293T cells. 
Transfection complexes were generated by adding DNA and Genecellin transfection reagent (Bulldog 
Bio) in a 1:6.7 ratio (0.9 µg gp160 + 1.8 µg pSG3Δenv + 18 µl Genecellin), to 200 µl of serum-free 
medium. Transfection mixes were vortexed for 3 seconds and incubated at room temperature for 15 
minutes. Medium was removed from each well and replaced with 2 ml of fresh medium before adding 
complexes in a drop-wise fashion. Cells were incubated for 48 hours at 37 °C before harvesting PSVs. 
Growth medium was collected from each well and placed into 2 ml syringes. Medium was then filtered 
into 15 ml tubes through 0.2 µm filters. 200 µl of FBS was added to obtain a final concentration of 10% 
FBS. The medium was mixed thoroughly and aliquoted into Eppendorf tubes (50 µl) for p24 ELISA and 
the remainder into cryovials for long-term storage at -80 °C. The cells left in the plate were then lysed 
using RIPA buffer (see section 2.3.3 on cell lysis) for Western blot analysis. 
 2.3.8.3  Pseudovirus production in CHO cells 
CHO cells were seeded and incubated as described above for HeLa cells with the following changes; 
transfection complexes were generated by adding DNA and Genecellin transfection reagent (Bulldog 
Bio) in a 1:6.7 ratio (1.1 µg gp160 + 2.2 µg pSG3Δenv + 22 µl Genecellin), to 200 µl of serum-free 
medium. PSVs were stored at -80 °C and cells were lysed as described above (section 2.3.3). 
 2.3.9   p24 ELISA 
 2.3.9.1  Coating p24 ELISA plates 
High binding 96-well plates (Sigma, # CLS3922-100EA) were coated with lyophilised sheep anti-HIV 
p24 Gag, affinity purified coating antibody (5.5 ng/ml) diluted 1:600 with 1x NaHCO3 (pH 8.5). 100 µl 
of the diluent was added to each well and left at room temperature overnight. The next day, plates 
were washed twice with 1x TBS, then left for one hour at room temperature with 100 µl of 5% BSA in 
each well. Plates were stored at -20 °C until needed.  
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2.3.9.2   p24 ELISA assay 
Before performing this assay, viruses were inactivated with 200 µl of 1.25% Empigen per 50 µl of virus 
sample, for one hour at room temperature. Standards were prepared with lyophilised recombinant 
HIV-p24 (Aalto #AG6054) at concentrations; 32, 16, 8, 4, 2, 1, 0.5 and 0 ng/ml. Virus samples were 
diluted with 1% Empigen (in 1x TBS) between 10 and 800 x depending on the sample. 100 µl of each 
standard was added to the plate in duplicate. 100 µl of each sample at each concentration was added 
to the plate in duplicate or triplicate. The plate was left at room temperature for three hours. TROPIX 
buffer (Applied Biosystems) was diluted to 1x with dH2O. Secondary conjugate was prepared by 
diluting conjugate (EH12AP (Aalto Bioreagents # BC-1071-AP)) in 1x TBS, 20% sheep serum (Lasec), 
0.05% Tween (Sigma), and 8% BSA. After three hours of incubation, plates were washed four times 
with 1x TBS. 100 µl of conjugate was added to each well and left to incubate for one hour at room 
temperature. Thereafter, plates were washed eight times with 1x TBS and twice with 1x TROPIX buffer. 
50 µl of ELISA CPD Star/Sapphire II (Applied Biosystems, # T1025), diluted 1:4 with 1x TROPIX buffer, 
was added to each well and left to incubate at room temperature for two minutes before reading in 
the luminometer.  
 
 2.3.9.3  Ultracentrifugation of Pseudoviruses 
After generated PSVs were shown to have very low p24 concentrations, ultracentrifugation was used 
to concentrate the PSVs. Transfections were performed as described above (section 2.3.8) for each 
cell type and 6 wells were pooled for each sample in order to concentrate the samples. The samples 
were layered onto a 1 ml, 20 % glycerol cushion and ultracentrifuged at 26 000 rpm for two hours at 
4 °C. The supernatant was carefully poured off and the pellets were resuspended in the remaining 
supernatant. The samples were stored at -80 °C until needed. 
 
 2.3.10  Titration of Pseudoviruses in TZM-bls 
TZM-bls were plated in 96-well plates at a density of 1 x 104 cell per well and left to incubate overnight 
at 37 °C. PSVs were allowed to thaw at room temperature and then serially diluted in a deep-well 
plate. Concentrations of p24 were as follows: 100 ng/ml, 50 ng/ml, 25 ng/ml and 12.5 ng/ml. 100 µl 
of medium was removed from the cell culture and 100 µl of each virus dilution was added to the 96-
well plate in triplicate. The cells were incubated for 48 hours before lysis. For cell lysis, 150 µl of 
medium was removed from each well, such that 50 µl remained. 50 µl of BrightGlo was then added, 
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mixed thoroughly and then transferred to an opaque 96-well plate and left to lyse for 2 minutes before 
reading in the luminometer.  
 
 2.3.11   Generating infectious molecular clones 
 2.3.11.1 Amplification of the env gene  
The env gene was polymerase chain reaction (PCR) amplified using Platinum Taq High Fidelity 
Polymerase (Invitrogen®), from the CAP210 E8 plasmid with the following primers: 
Forward primer: 5’- AGAAAGAGCAGAAGACAGTGGCAATGA – 3’ 
Reverse primer: 5’ – TTTTGACCACTTGCCACCCAT – 3’ 
The reaction components and PCR cycling conditions can be seen in Table 2.1 and Table 2.2 below. 
Table 2.1: Components and final concentrations for reaction mixes. 
Reaction component Concentration 
Buffer 1 x 
MgSO4 1.5 mM 
dNTPs 0.2 mM 
Forward primer 0.2 µM 
Reverse primer 0.2 µM 
Q5 Taq polymerase 1 ng 
H2O up to 50 µl 
DNA template 1 U 
 
Table 2.2: Cycling conditions for PCR to amplify env gene. 
Cycle Temperature (°C) Time (minutes) 
Initial denaturation 94 2 
Denaturation 94 0.5 
Annealing 55 0.5 
Extension 72 2.5 
 
Amplification of the desired product was confirmed by agarose gel electrophoresis. 5 µl of the PCR 
product was loaded to a 0.8 % agarose gel with ethidium bromide and run for an hour at 80 V. Once 
the presence of the 3 kb product was confirmed, the remaining PCR products were purified using the 
Wizard® SV Gel and PCR Clean-Up kit (Promega®), following the manufacturer’s instructions. 
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 2.3.11.2 Linearising the Q23 vector 
For homologous recombination to take place between the env gene and the Q23 vector, the vector is 
required in a linear conformation. To generate linear Q23, the DNA was digested with the SalI 
restriction enzyme (NEB) for one hour at 37 °C. See table 2.3 for reaction components. 
Table 2.3: Components added to the digestion reaction of Q23. 
 
 
To confirm that the Q23 vector was linearised in the digestion reaction, the product was run on a 0.8 
% agarose gel and visualised. After confirming digestion, the remainder of the products was run on a 
0.8 % agarose gel and the linear band was excised from the gel. The gel slice was purified using the 
Wizard® SV Gel and PCR Clean-Up kit (Promega®), according to the manufacturer’s instructions.  
 
 2.3.11.3 Generating competent yeast cells 
To generate competent yeast cells, 10 ml yeast extract peptone dextrose (YEPD) medium (1% yeast 
extract, 2% peptone, 2% dextrose) was inoculated with 100 µl of S288C yeast cells and incubated at 
30 °C overnight, with shaking. OD readings were taken at 600 nm by diluting the overnight culture 
1:10 in YEPD. Once the absorbance was established, the cultures were diluted to OD600 = 0.3. The 
diluted cultures were then incubated again for 1 – 2 hours until the OD600 readings reached 1.2. The 
cultures were then centrifuged at 3 000 rpm for 5 minutes. The pellet was resuspended in dH2O in half 
of the volume of the original yeast culture. The supernatant was discarded, and the pellet was 
resuspended in 1 ml 10 % glycerol per 50 ml of culture medium. Cells were then divided into 100 µl 
aliquots and stored at -80 °C until needed.  
 
 2.3.11.4 Transforming competent yeast cells 
Salmon sperm DNA (Invitrogen®) was placed in the heating block at 95 °C for 3 minutes and then on 
ice for 2 minutes. Competent S228C cells were thawed on ice and centrifuged at 3 000 rpm for 5 
minutes and the supernatant was discarded. To transform the yeast cells, the following reagents were 
added as seen in Table 2.4 below: 
Component Concentration 
Buffer 1 x 
SalI enzyme 1 U 
DNA 250 ng 
H2O up to 50 µl 
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Table 2.4: Components making up the transformation reaction. 
Component  Concentration/Volume 
Insert (env PCR product) 1 µg 
Vector (linearised Q23) 0.2 µg 
Salmon sperm DNA 10 µl 
50 % Polyethylene glycol 240 µl  
1 M lithium acetate 36 µl  
dH2O up to 370 µl  
 
The mixture was incubated at 30 °C for 30 minutes, then transferred to 42 °C for 15 minutes. Tubes 
were centrifuged for 30 seconds at maximum speed, the supernatant was discarded, and the pellets 
were resuspended in 100 µl of Tris-EDTA (TE) buffer. The total volume was spread onto yeast amino 
acid dropout plates + 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidine carboxylic acid (FOA), 2% 
peptone, 1% yeast extract, 2% w/v agar, 0.67% w/v complete supplement mixture minus leucine 
(CSM-leu), 2% dextrose, 0.1% w/v FOA). The plates were then incubated at 30 °C for 2 – 3 days.  
  
After incubation, positive colonies were screened by colony PCR using the following primers: 
Forward yeast primer: 5’ AAT GTC AGC ACA GTA CAA TGT ACA CAT GG 3’ and Reverse yeast primer: 5’ 
GGA GCT GTT GAT TTA GGT ACT TTT 3’. The reaction was set up and performed as seen in Table 2.5 
and Table 2.6 below. 
 
Table 2.5: Components for yeast colony PCR. 
Reaction Component  Concentration (final) 
Buffer 1 x 
dNTPs 0.2 mM 
Forward primer 0.2 µM 
Reverse primer 0.2 µM 
DNA Tip full 
Taq  1 U 
dH2O up to 25 µl 
 
Table 2.6: Cycling conditions for yeast colony PCR. 
Cycle Temperature (°C) Time (minutes) 
Initial denaturation 95 0.5 
Denaturation 95 0.5 
Annealing 55 1 
Extension 68 1 
Final extension 68 5 
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The PCR was carried out using Q5 High Fidelity Polymerase kit (Inqaba Biosystems®). The presence of 
a ~3 kb band was confirmed by gel electrophoresis on a 0.8 % agarose gel. Positive colonies were 
selected and YEPD was inoculated with each positive sample. The cultures were incubated with 
shaking at 30 °C overnight. The DNA was extracted from the yeast cells using the Zymoprep™ 
Yeast Plasmid Miniprep Kit (Zymo Research Corporation®) and sent for sequencing by Central 
Analytical Facility (CAF). Sequencing results were then analysed using Chromas Pro to confirm the 
product. 
 2.3.11.5 Electroporation of electrocompetent E. coli  
Extracted DNA was electroporated into electrocompetent E. coli β-10 cells (NEB) following the 
manufacturer’s instructions. 100 µl of the cells was plated onto LA + 100 µg/ml carbenicillin disodium 
salt and the plates were incubated at 30 °C overnight. After incubation, colonies were selected and 
screened by PCR as described in section 2.3.11.1. DNA was sent for sequencing by CAF. The sample 
that returned the best sequencing results was taken forward for generating IMCs, Q23.6. 
 
 2.3.11.6 Transfections to generate infectious molecular clones in HEK293T cells 
HEK293T CHO cells were seeded in 6-well plates at a density of 2 x 106 cells per ml in 2 ml final volume 
and left to incubate overnight at 37 °C, 5 % CO2 in a water-jacket incubator. Cells were allowed to 
reach ~40 – 60 % confluency prior to transfection. To form transfection complexes, 1 µg of Q23 helper 
plasmid DNA, 1 µg of Q23.6 DNA and 0.2 µg of pGL4-luc was mixed in 400 µl of serum-free medium. 
Thereafter, 6 µg of PEI was added, and samples were vortexed for 15 seconds before incubating at 
room temperature for 10 minutes. The complexes were then added to the cells after replacing the 
cells with fresh medium. The cells were left to incubate at 37 °C, 5 % CO2 in a water-jacket incubator 
for 48 hours. After 48 hours, the cells were lysed as described in section 2.3.3. 
 
 2.3.11.7 Transfections to generate infectious molecular clones in HeLa and CHO 
   cells 
The same procedure as described in section 2.3.11.6 was followed using 6 µl of Genecellin instead of 
PEI to form transfection complexes. All IMCs were ultracentrifuged following the same procedure 
described in section 2.3.10. After ultracentrifugation, IMCs were quantified by p24 ELISA as outlined 
in section 2.3.9.2.  
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 2.3.12  Replication Kinetics 
 2.3.12.1 Isolation of peripheral blood mononuclear cells 
Whole blood buffy packs were collected from the Western Province Blood Transfusion Service 
(WPBTS).  Donors were all confirmed to be healthy after being tested for Hepatitis B and C, HIV-1 and 
syphilis. For the isolation of peripheral blood mononuclear cells (PBMCs), 15 ml of Histopaque (Sigma-
Aldrich®) was added to Leucosep tubes (Greiner Bio-One®) and centrifuged at 2 500 rpm for 1 minute. 
Whole blood samples were diluted in a 1:1:1 ratio with Roswell Park Memorial Institute (RPMI) 
medium (Lonza®) and PBS (Lonza®). The total volume was added to the pre-centrifuged Leucosep tube 
which were centrifuged again at 2 500 rpm for 15 minutes. The centrifugation led to the separation of 
the blood into three layers. The top layer contained the plasma, the middle layer contained the PBMCs 
and the bottom layer contained the erythrocytes (Figure 2.1). 
 
 
 
 
 
Figure 2.1: Diagram showing the separation of blood samples after centrifugation in Leucosep tubes with Histopaque Image taken from 
https://bio-protocol.org/e1300. 
A Pasteur pipette was used to remove the PBMCs without disrupting the other layers to ensure that 
only PBMCs were collected. The PBMCs were collected into a clean 50 ml tube with 30 ml of PBS 
supplemented with 1 % FBS to wash the cells. The cells were pelleted by centrifuging at 1 200 rpm for 
5 minutes. This wash step was repeated two to three times and after the final wash, 10 µl of cell 
resuspension was added to 90 µl of Trypan Blue (Lonza®) for counting on a haemocytometer. To make 
cell stocks, cells were centrifuged at 1 500 rpm for 8 minutes and stored in 10 % DMSO in FBS at a 
concentration of 20 – 50 million cells per ml, in 1 ml aliquots at -80 °C until required. 
 
 2.3.12.2 Activation of peripheral blood mononuclear cells 
PBMC stocks were thawed, counted and seeded at a density of 1 million cells per ml in a final volume 
of 10 ml in a T25 flask (NEST®). The RPMI medium was supplemented with 10 % FBS, 200U/ml 
Interleukin-2 (IL-2) (Gentaur®) and 0.5 µg/ml phytohemagglutinin-P lectin (PHA-P) 
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(ThermoScientific™) to activate replication. These activated PBMCs were left to incubate at 37 °C 5% 
CO2 in a water-jacket incubator for 72 hours.  
 
 2.3.12.3 Testing donors for ability to support replication 
To ensure that PBMCs isolated from each donor are able to support replication, cells were tested by 
infection with IMCs. After activation, the cells were counted and plated at a density of 106 cells per ml 
in a 96-well plate and infected with 40 000 ng p24 IMCs. To enhance infection of PBMCs, the 96-well 
plates were spinoculated by centrifugation at 1 500 x g for 2 hours at room temperature. The plates 
were incubated at 37 °C in 5 % CO2 in a water-jacket incubator for a total of 14 days. 50 µl of culture 
medium was harvested on days 4, 7, 10 and 14 and cells were replenished with 50 µl of fresh medium 
after each harvest. The harvests were stored at -80 °C until required. To determine whether the PBMCs 
were able to support replication of the IMCs, the 50 µl harvests were tested by a p24 ELISA assay as 
described in section 2.3.9.2.  
 
 2.3.12.4 Expansion of infectious molecular clones 
Due to low virus yields of IMCs as determined by p24 ELISA, IMCs were expanded in PBMCs to obtain 
higher virus titres. PBMCs were isolated and activated, as described above (section 2.3.12.1), and 
seeded in 6-well plates at a concentration of 5 x 106 cells per well in 2 ml RPMI supplemented with IL-
2 and PHA-P. Each well was infected with a different virus using the total available virus, due to low 
yields. The cells were then spinoculated as mentioned above (section 2.3.12.3). After spinoculation, 
cells were removed from the 6-well plate and cultured upright in T25 flasks in a final volume of 5 ml 
supplemented RPMI medium. Cells were incubated at 37 °C in 5 % CO2 for 4 days. After 4 days the 
infected cells were harvested, counted and replenished with fresh supplemented RPMI to obtain a 
concentration of 1 million cells per ml. The cells were incubated at 37 °C in 5 % CO2 for another 3 days. 
PBMCs were activated as described above -in preparation for the next step of expansion. After 3 days, 
the infected cells were harvested, counted and resuspended in supplemented RPMI to obtain a final 
concentration of 1 million cells per ml. The supernatants, containing virus, from each sample was 
collected and ultracentrifuged as described in section 2.3.9.3 to concentrate the virus and determine 
p24 concentration. The activated PBMCs were also harvested, counted and resuspended in 
supplemented RPMI to a final concentration of 1 million cells per ml. Thereafter, 5 ml of activated 
PBMCs was added to each of the expanding virus samples and left to incubate for another 3 days. 
Once again, fresh PBMCs were activated. The same procedure was repeated until the viruses had been 
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expanded for a total of 17 days. After p24 ELISAs were performed, many samples were too low to 
quantify. Thus, day 17 samples were assumed to have the highest viral titres and were carried forward.  
 
 2.3.12.5 Entry efficiency of infectious molecular clones  
Since only approximately 100 µl of concentrated virus was obtained per sample, non-concentrated 
viruses were used to infect TZM-bls. TZM-bls were seeded as described in section 2.3.10. Each virus 
was used to infect TZM-bls in duplicate with 11 serial dilutions, beginning with undiluted supernatants. 
The infected TZM-bls were incubated at 37 °C in 5 % CO2 for 72 hours. Cells were then lysed and 
quantified as described in section 2.3.10. 
 
 2.3.12.6 Replication of infectious molecular clones in peripheral blood   
   mononuclear cells 
To test replicative fitness of each virus, PBMC stocks, which had previously been determined to be 
capable of supporting viral replication, were activated and seeded as described in section 2.3.12.3. To 
normalise the amount of viruses added, the entry efficiency data was used. All samples were 
normalised to 15 x background luminescence obtained by the infection of TZM-bl cells. CHO cells 
produced substantially lower readings, therefore the total volume of virus was used for the infection. 
After normalising, 100 µl of each sample was used to infect the activated PBMCs. The infected cells 
were spinoculated as described previously (section 2.3.12.3) and incubated at 37 °C in 5 % CO2. 50 µl 
of supernatant was harvested on days 4, 7, 10, 14 and 17 and quantified by p24 ELISA. On each harvest 
day, the cells were replenished with 50 µl of fresh supplemented RPMI.  
           
2.4  Statistical analysis 
All statistical tests were conducted using Prism 5.0 and graphs presented in this thesis were generated 
using Microsoft Excel.  
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Chapter 3 
Determining whether pseudovirus and infectious molecular clones differ in HIV-1 Envelope 
expression, processing and incorporation into viral particles 
3.1 Introduction 
Thus far, there have been conflicting reports on whether pseudovirus (PSV) and infectious molecular 
clones (IMC) are directly comparable (Table 1.2) due to differences in Env expression and processing 
when produced within the context of these two experimental approaches 10-12. Variation in Env 
expression can affect incorporation into budding virus as shown by Bachrach, et al. 54 who 
differentially expressed Env using an inducible vector and found that changes in expression directly 
influenced the number of Env proteins incorporated into viral particles 54. Another study showed that 
there was a direct link between Env expression, incorporation and PSV infectivity 96. Furthermore, 
changes in Env expression has been indirectly linked to changes in N-glycosylation based on the impact 
of the Env signal peptide on expression and N-glycosylation 97, suggesting that factors that influence 
Env expression will impact overall Env processing and viral infectivity. As vaccine design requires that 
Env elicits a broadly neutralising immune response, factors that alter Env processing will most likely 
interfere with antigenicity and thus expression systems need to be carefully considered when 
generating vaccine candidates 98. 
Env clones are expressed differently even when cloned into the same mammalian vector 99, and 
differentially glycosylated depending on the cell type used for expression 28. Therefore, in this study 
HEK293T, CHO and HeLa cells were compared because they are most commonly used in studies that 
investigate HIV-1 Env expression, N-glycosylation, function, production of PSVs and IMCs as well as 
production of vaccine candidates 100 101. As different Env clones might have varied expression due to 
genotypic and/or phenotypic differences, we tested two subtype C clones, CAP210 E8 and Du151a. 
Previous studies in our lab have shown that cell-associated Env usually represents under processed 
protein (unpublished data). To compare N-glycosylation of mature Env, CAP210 E8 was truncated to 
form gp140, by removing the transmembrane region and generating a soluble construct that is 
released into the culture medium once trafficked to the plasma membrane 102. Furthermore, as Env 
expression could be influenced by the presence of other viral proteins, we investigated expression in 
the presence of PSV backbones pSG3Δenv (pSG3) 103 and DHIV-pNL4-3-E-R (pNL4.3) 104. Similarly, for 
IMC production, the backbones pNL4.3 and Q23 5 were used. Therefore, this chapter will report on 
how Env expression, incorporation and N-glycosylation are impacted by cell-type, HIV backbones and 
systems for generating PSVs and IMCs. 
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3.2 Results 
 3.2.1 Generating infectious molecular clones 
In order to determine whether IMC backbones impact Env expression, processing and viral replication, 
CAP210 E8 was inserted into the pNL4.3 (Bahiah Meyer, MSc student in our lab) and Q23 backbones 
by homologous yeast recombination.  
 3.2.1.1  PCR amplification of env 
CAP210 E8 was cloned into the mammalian expression vector, pCDNA3.1_TOPO (Invitrogen) (kind gift 
from Prof Carolyn Williamson) using single-genome amplification and primers complimentary to vpu 
and nef. To generate IMCs, CAP210 E8 was amplified from pCDNA3.1_TOPO using primers designed 
to regions that flanked env. (Forward primer, Env F: 5’- AGAAAGAGCAGAAGACAGTGGCAATGA – 3’ 
Reverse primer, Env R: 5’ – TTTTGACCACTTGCCACCCAT – 3’). The PCR was carried out in duplicate to 
obtain sufficient product following purification. The presence of a ~ 3 kb band, the same size as the 
positive control (amplified env of the pN4.3 provirus) indicated that the correct product had been 
generated (Figure 3.1). This band was subsequently excised from the agarose gel and purified for 
ligation into the linearised Q23 vector.  
 
 
 
 
 
 
 
 
 
 3.2.1.2 Screening of transformed yeast colonies 
Q23 was digested with SalI located within the URA gene that neutralises the activity of 5-fluoro-
1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidine carboxylic acid (FOA) a compound toxic to yeast cells. Thus, 
when transformed cells were grown on FOA+ plates, only those colony forming units (cfu) with a URA 
gene disrupted by the insertion of env would grow. Yeast cells were transformed with env PCR product 
Figure 3.1: PCR amplification of CAP210 E8. Primers flanking the env gene of CAP210 E8 were used to 
amplify the gene in preparation for the homologous recombination assay. -ve indicates the negative 
control, pNL4.3 was used as a positive control, CAP210 E8 gp160 is the plasmid containing the env gene of 
interest. The reaction was performed in duplicate. The gene of interest is present at ~ 3 kb which is the 
same size as the positive control and therefore verified as the correct product. 
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and linear Q23 for homologous recombination. Following transformation, the yeast cfu were screened 
by PCR to determine which colonies contained the env gene. Colony PCR was carried out using primers 
located within env so that a PCR product of 1 kb indicated the presence of env within Q23. The agarose 
gel revealed that cfu 2, 3, 4, 5, 6, 7 and 8 were positive for the presence of the env (Figure 3.2). These 
colonies were thus carried forward for plasmid extraction and subsequent electroporation into E. coli. 
 
 
 
 
 
 
 
 
 3.2.1.3 Electroporation of E. coli 
The plasmid DNA from the positive yeast cfu identified in section 3.2.1.2 was extracted and 
electroporated into electrocompetent E. coli cells. The colonies were screened by PCR to identify 
which colonies contained the env gene. A band was detected at the expected size of ~ 1 kb, however, 
due to the presence of a band in the negative control, we could not be sure that the samples 
expressing a band at 1 kb were true positive colonies (Figure 3.3). To confirm which colonies contained 
the env gene and to check for any mutations which many have occurred during the cloning process, 
these samples were all sent for sequencing. 
 
 
 
 
 
 
  
Ladder -ve 1 2 3 4 5 6 7 8 9 
3 kb 
1 kb 
6 kb 
gp160 
Figure 3.2: Colony PCR of transformed yeast cells. Following transformation of yeast cells with the env PCR product and 
linear Q23 HIV-1 IMC backbone, 9 colonies were selected for colony PCR to determine which colonies contained the env 
gene. –ve indicates the negative control: water only PCR, 1-9 indicates the colonies that were chosen for screening. The 
molecular weight marker (Biorad) is indicated. 
Ladder -ve 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
6 kb 
3 kb 
1 kb gp160 
Figure 3.3: Colony PCR of electroporated E. coli cells. After electroporation of E. coli cells with the plasmid DNA extracted 
from the yeast cfu, PCR was used to screen 15 E.coli cfu for the presence of env. -ve indicates the negative control: water 
only PCR, 1-15 indicate the colonies that were selected for screening.  The arrow indicating gp160 refers to the 1kb band 
expected for positive colonies 
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 3.2.1.4  Sequencing results of E. coli colonies 
Sequences were aligned in BioEdit using the CAP210 E8 sequence as a reference. The colony chosen 
for subsequent experiments was shown to align to the reference sequence, indicating that a chimeric 
IMC – Q23_CAP210 E8 – which contained the env gene had been constructed (See appendix Figure A1 
for full sequence alignment). 
 3.2.2 Cell types influence expression and processing of Env  
 3.2.2.1 Optimising transfections in HeLa and CHO cells 
The protocol for transfection of HEK293T cells has been optimised in our laboratory. However, this 
method did not yield positive results for HeLa and CHO cells with regard to Env expression and PSV 
and IMC production, and thus extensive optimisation was carried out. Table 3.1 shows the parameters 
that were modified to optimise transfections using various commercial transfection reagents. In 
addition, we also attempted to optimise DNA complex formation and cell lysis by varying the duration 
of these crucial steps. We identified that Genecellin with a ratio of 1:3 DNA:transfection reagent 
yielded the best results and this protocol was used for all subsequent experiments. 
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 3.2.2.2 Transfection efficiency  
HEK293T, HeLa and CHO cells were co-transfected with either CAP210 E8 or Du151a and pGL4-luc, 
with the latter controlling for transfection efficiency via expression of the firefly luciferase gene. Cell 
types take up plasmid DNA at different efficiencies due to cell-specific expression of factors that 
facilitate uptake. For example, endocytosis and transport into the nucleus 105. Therefore, differences 
in expression of Env might be due to variable transfection efficiency, both within and between 
experiments, and not intrinsic differences in gene-specific expression. After co-transfections of all 
samples and cell lysis, the intracellular expression of pGL4-luc was quantified using a luminometer. 
Figure 3.4 represents the transfection efficiency of 5-10 independent transfection experiments and 
statistical analysis indicated that there was no difference in expression between samples, suggesting 
that efficiency of the transfections should not influence the comparison of Env expression between 
cell types. However, to ensure accuracy, all expression, and incorporation data were normalised to 
the respective transfection efficiencies.  
Table 3.1: Optimisation of transfection of pGL4-luc in HeLa and CHO cells using luciferase assay. 
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 3.2.2.3 Comparison of Env expression in different cell lines  
Comparison of CAP210 E8 gp160, CAP210 E8 gp140 and Du151a gp160 levels, normalised to their 
respective β-actin loading controls and transfection efficiencies, indicated that HEK293T, HeLa and 
CHO cells expressed recombinant CAP210 E8 to similar degrees (Figure 3.5). Although not significant, 
CAP210 E8 gp140 expression was about 2-fold higher in HeLa cells compared to HEK293T and CHO 
cells. Du151a however was differentially expressed in CHO cells as gp160 levels were 16- and 15-fold 
higher than when produced in HEK293T and HeLa cells, respectively (Figure 3.6 D). This suggested that 
differences in expression of Env clones can vary depending on the cell type. For example, Du151a and 
CAP210 E8 gp160 are expressed similarly in HEK293T cells but differently in CHO cells.  Therefore, the 
selection of cell type to compare the expression of different recombinant Envs will influence 
experimental outcome. 
 
  
 
 
Figure 3.4: Transfection efficiency in HEK, HeLa and CHO cells. Cells were co-transfected with either CAP210 E8 (gp160, 
gp140), Du151a or pcDNA and pGL4-luc to measure efficiency at which plasmids were taken up and expressed by the 
different cells. The box and whisker plot depicts the efficiencies for samples transfected into three cell lines. Each box 
represents the distribution of RLU for 5-10 experiments which each had duplicate measurements. The duplicates were 
averaged and plotted above. Column statistics analyses was carried out using Prism 5.0 and showed no significant 
differences between transfection efficiencies between any of the samples. 
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 3.2.2.4 Effect of cell line on apparent molecular weight of Env  
Western blotting indicated that molecular weights (MW) of Env varied across cell lines (Figure 3.5) 
(Table 3.2).  When CAP210 E8 was expressed in HEK293T cells, there was only a very faint band 
corresponding to gp120 (approximately 150 kDa).The band representing CAP210 E8 gp160 
corresponded to approximately 170 kDa, 187 kDa and 211 kDa in HEK293T, HeLa and CHO cells, 
respectively. Du151a gp160 and gp120 was approximately 189 kDa and 161 kDa in CHO cells, 
respectively; 192 kDa and 166 kDa in HEK293T cells, respectively; and 151 kDa and 132 kDa in HeLa 
Figure 3.5: Expression of CAP210 E8 gp160, CAP210 E8 gp140 & Du151a gp160 in HEK293T, HeLa & CHO cells.  A) 
Representative of 3 Western blots showing expression of gp160, gp140 & gp120 in CAP210 E8 and Du151a in CHO cells. B) 
Representative of 3 Western blots for HEK293T cells. C) Representative of 3 Western blots for HeLa cells. 100 µg total protein 
was run on an SDS-PAGE gel and visualized via Western blot. Anti-gp120 antibody was used to detect gp120, gp160 and 
gp140 while anti-β-actin was used to detect β-actin. ‘+’ indicates gp120 positive control, pcDNA was used as a negative 
control. β-actin was used as the loading control. D) Densitometry (ImageJ) was used to determine the relative intensities of 
bands representing Env and β-actin for three independent Western blots. The average densitometry of Env of the three 
independent Western blots were normalised to that of β-actin as well as the respective transfection efficiency for each 
transfection experiment. Bars represent average relative expression and error bars represent standard deviation of the three 
Western blots for each cell line. Statistical analysis by one-way ANOVA conducted in Prism 5.0 showed no significance. 
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cells, respectively. There was a similar difference in MW between gp160 Du151a and gp160 CAP210 
E8 in HEK293T and CHO cells (22 kDa) although CAP210 E8 was larger than Du151a when expressed 
in HEK293T cells but smaller when expressed in CHO cells. On the other hand, expression of gp160 
CAP210 E8 was 36 kDa larger than Du151a when both clones were expressed in HeLa cells. As Env is 
highly N-glycosylated and glycosidase expression is highly dependent on cell type 28, variation in MW 
is likely due to different cellular glycosylation machinery. When the sizes of CAP210 E8 gp160 and 
gp140 were compared across all cell types, gp160 MW varied from 211 – 170 kDa and gp140 ranged 
from 189 – 151 kDa. Similarly, Du151a also showed varying MW with gp160 ranging from 192 – 151 
kDa and 166 – 132 kDa for gp120. Although we must take into account the limitation of SDS-PAGE to 
determine MW, overall, this suggests that cell types differentially glycosylated Env. 
 
 
 
 
Cell line 
CAP20 E8 * Du151a # 
gp160 gp140 gp160 
gp160 (kDa) gp120 (kDa) gp140 (kDa) gp120 (kDa) gp160 (kDa) gp120 (kDa) 
HEK293T 170 150 159 134 192 166 
HeLa 187 169 151 Not detected 151 132 
CHO 211 192 189 Not detected 189 161 
 
 
 
 
 3.2.2.5 Cleavage of Env in different cell lines  
Cleavage of gp160 and gp140 is influenced by folding, trimerisation and N-glycosylation of Env as these 
factors influence the ability of furin to gain access to the cleavage site 106. Therefore, one of the aims 
of this study was to compare the level of cleavage of Env in different cell lines noting that they express 
different levels of furin 107.  
Uncleaved cell-associated gp160 can occur as a doublet with the higher MW of the two bands 
representing heavily sialylated Env. Furthermore, sialylated uncleaved gp140 occurs as a smear which 
might mask gp120 leading to underestimation of cleavage 108. It was thus a challenge to determine 
cleavage of CAP210 E8 gp160 and gp140 using cell-associated samples. The use of a gp41-specific 
antibody would have distinguished gp120 from gp160, but our laboratory was unable to generate 
Western blots using anti-gp41 antibodies.  
Table 3.2: Molecular weight of CAP210 E8 and Du151a expressed in different cell lines.  
* The MW of CAP210 E8 gp160, gp120 and gp140 were determined using the molecular weight marker of one Western 
blot used to measure Env cleavage (Figure 3.6). 
# The MW of Du151a gp160 and gp120 were determined using the molecular weight marker of three independent 
Western blots used to measure Env expression (Figure 3.5) 
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When CAP210 E8 was expressed in the various cell types, cleavage was not consistently detected 
(Figure 3.5). Figure 3.6 shows an example Western blot of an instance when gp160 cleavage was 
apparent. CAP210 E8 gp160 cleavage in HEK293T cells resulted in a weak gp120 band (Figure 3.6 A) 
suggesting that HEK293T cell proteases are inefficient at CAP210 E8 cleavage. This finding supports 
previous data which showed that Env cleavage occurs poorly in Env-transfected cells resulting in an 
accumulation of intracellular gp160 106,109 and that HEK293T cells produce low levels of furin 107. 
CHO cell proteases cleaved Du151a gp160 3-fold higher than HEK293T and 5-fold higher than HeLa 
cells. As we were unable to consistently show cleavage of CAP210 E8, we could not directly compare 
it to that of Du151a, but apparently, Du151a is more susceptible to cleavage than CAP210 E8. CHO 
cells might be better at Env cleavage as it was previously shown to produce a number of proteases, 
including furin that are able to cleave gp160 110. Overall, this would suggest that like expression, 
cleavage is also cell type-specific and dependent on the Env clone analysed.  
When gp140 was expressed in HEK293T cells a band corresponding to approximately 120 KDa was 
detected (Figure 3.5 A). However, this band did not represent gp120 because it did not correspond to 
the size of gp120 (150 kDa) when gp140 was expressed in HEK293T cells (Figure 3.5 A) and was most 
likely a degradation product. We were thus unable to determine the cleavage efficiency of CAP210 E8 
gp140 (Table 3.2) possibly because the gp140 and gp120 bands were not resolved due to similar MW 
and extensive N-glycosylation. 
Previous studies have shown that HeLa cells express higher levels of furin than HEK293T cells and that 
in CHO cells furin is not the only protease responsible for Env cleavage 107,110. Our results support these 
findings as CHO apparently cleaved Du151a and CAP210 E8 better than HeLa cells and both cell lines 
cleaved Env better than HEK293T cells. It has been reported that furin cleaves gp160 very inefficiently 
and some Envs are resistance to cleavage even when co-expressed with high levels of furin. Moreover, 
over-expression of furin resulted in a decrease in Env expression suggesting that this could be one 
reason why some cell lines express low levels of Env but exhibit high cleavage efficiency 106.  
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Figure 3.6: Expression of CAP210 E8 gp160, CAP210 E8 gp140 & Du151a gp160 in HEK293T, HeLa & CHO cells.  A) 
Representative of 3 Western blots showing expression of gp160, gp140 & gp120 in CAP210 E8 and Du151a in HEK293T 
cells. B) Representative of 3 Western blots for HeLa cells. C) Representative of 3 Western blots for CHO cells. 100 µg total 
protein was run on an SDS-PAGE gel and visualized via Western blot. Anti-gp120 antibody was used to detect gp120, 
gp160 and gp140 while anti-β-actin was used to detect β-actin. β-actin was used as the loading control. D) Representative 
of 3 Western blots showing Du151a cleavage. Expression was normalised to β-actin and transfection efficiencies to 
compare across cell types. 
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 3.2.2.6  Transfection efficiency of pseudovirus  
As in section 3.2.2.1, transfections to produce pseudovirus included co-transfection of pGL4-luc to 
determine the variability in transfection efficiency. Figure 3.7 shows that there was no significant 
difference in transfection efficiencies across Env constructs but there did seem to be a trend where 
HeLa cells were less easily transfected than the other cell types. We therefore normalised all 
expression data to transfection efficiency.  
 
 
 
 
 
 
 
 
 
 
 
 3.2.2.7 Determining the effect of viral proteins on Env expression 
Despite high transfection efficiency of pGL4-luc, the expression of cell-, PSV- and IMC-associated Env 
was very low as determined by Western blotting. In many cases, we were unable to detect Env by 
Western blotting if we normalised cell lysates to 100 ng total protein or PSV and IMC samples 
according to p24 levels determined by ELISA. In the case of virus production, culture medium 
containing PSV and IMC was first ultracentrifuged to concentrate virus. To maximise the chance of 
detecting Env we then loaded the maximum sample volume allowed per well (16 ul). After Western 
blotting Env densitometry was normalised to that of the loading controls (p24 or β-actin). 
 3.2.2.7.1  Env expression during pseudovirion production  
Although expression levels of recombinant Env did not differ across cell types in general, CAP210 E8 
and Du151a were expressed and cleaved with differing efficiency as previously shown when Env 
clones JRFL and YU-2 were compared. This suggested that clones are differentially processed 108. In 
Figure 3.7: Transfection efficiency in HEK, HeLa and CHO cells to produce pseudoviruses. Cells were co-transfected 
with either CAP210 E8 and pSG3∆env pNL4.3-R-E-luc
+
 and pGL4-luc to measure efficiency at which plasmids were taken 
up and expressed by the different cells. The box and whisker plot depicts the efficiencies for samples transfected into 
three cell lines. Each box represents the distribution of RLU for 5-10 experiments which each had duplicate 
measurements. The duplicates were averaged and plotted above. Column statistics analyses was carried out using Prism 
5.0 and showed no significant differences between transfection efficiencies between any of the samples. 
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vivo expression of Env involves the presence and activity of other viral proteins and we thus 
determined whether co-transfection with the HIV backbone influenced Env expression and cleavage. 
For example, it has been shown that the co-expression of Gag influences the conformation and 
incorporation of Env into viral particles which might be linked to Env trafficking and processing111.  
Two different PSV backbones, pSG3∆env and pNL4.3-R-E-luc+ were included in co-transfections of 
HEK293T, HeLa and CHO cells with CAP210 E8 gp160. Western blot analysis showed that expression 
of Env with pSG3∆env and pNL4.3-R-E-luc+ was higher in HEK293T than in HeLa cells, although this 
difference did not reach statistical significance. There was no detectable Env in CHO lysates generated 
in the presence of both backbones. Env expression in the presence of HIV backbones is thus highly 
dependent on cell type and not affected by the type of backbone (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Cell-associated Env after co-transfection of different cell lines with PSV backbones. A) HEK293T, HeLa and 
CHO cells were co-transfected with CAP210 E8 and either pSG3∆env or pNL4.3-R-E-luc+. Co-transfection with pGL4_luc 
determined transfection efficiency. Cells were lysed after 48 hours, luminescence was determined using a luminometer 
and total protein concentration was determined. The Western blot was loaded with the maximum volume per well per 
sample and is a representative of two independent experiments. The blots were probed with sheep-anti-gp120 
antiserum and β-actin primary antibodies. B) Densitometry analysis was carried out using Image J and normalized to the 
b-actin loading control and transfection efficiency. The average relative expression of two independent Western blots 
are indicated with error bars representing Standard deviation. One-way ANOVA was carried out using Prism 5.0 for 
statistical analysis but yielded no significance. 
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 3.2.2.8 Transfection efficiency during production of infectious molecular clones 
As in sections 3.2.2.1 and 3.2.2.5, transfection efficiencies did not differ significantly when IMCs were 
generated using either Q23 or pNL4.3 (Figure 3.9). However, transfection efficiency of HeLa cells 
tended to be lower than the other cell lines and so we continued to normalise expression data to 
transfection efficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.2.2.8.1 Env expression during production of infectious molecular clones 
IMCs express env from the LTR of the HIV backbone in concert with other viral genes, 12 whereas 
recombinant Env expression is driven by the CMV promoter. Production of Env in the presence of 
other viral proteins might influence its expression, cleavage and incorporation into viral particles. We 
determined whether CAP210 E8 expression, when expressed as IMCs, was influenced by Q23 and 
pNL4.3 backbones. Compared to Env expression in the absence of other viral proteins, Env was 
undetectable in CHO cell lysates except for a faint band corresponding to Q23_CAP210 E8 (Figure 
3.10). HEK293T cells expressed higher levels of Env within the context of Q23 than pNL4.3, while HeLa 
cells expressed pNL4.3_CAP210 E8 better than Q23_CAP210 E8. Cleavage of gp160 was not detected 
for any of the samples. The differences in expression are likely due to host cell-specific factors that 
preferentially interact with viral proteins expressed by one backbone and not another and/or 
Figure 3.9: Transfection efficiency in HEK, HeLa and CHO cells during production of IMCs. Cells were co-transfected 
with either CAP210 E8 and pNL4.3 or Q23 and pGL4-luc to measure efficiency at which plasmids were taken up and 
expressed by the different cells. The box and whisker plot depicts the efficiencies for samples transfected into three 
cell lines. Each box represents the distribution of RLU for 5-10 experiments which each had duplicate measurements. 
The duplicates were averaged and plotted above. Column statistics analyses was carried out using Prism 5.0 and 
showed no significant differences between transfection efficiencies between any of the samples. 
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preferential binding of transcription factors to the LTR. Overall, this result suggests that when Env is 
expressed within the context of an IMC backbone, cell type and backbone identity influences 
experimental outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.2.2.8.2 Incorporation 
Due to the variation in expression and cleavage of Env that might impact incorporation and infectivity, 
we next compared incorporation of Env in PSVs and IMCs. Incorporation of high levels of uncleaved 
gp160 might affect the infectivity of PSVs and IMCs, noting that cleavage is essential for virion 
infectivity 112. 
 3.2.2.8.2.1 Incorporation of Env into pseudoviruses 
HEK293T, HeLa and CHO cells were transfected with pSG3∆env and pNL4.3-R-E-luc+ as described in 
chapter 2. Even though the harvested pseudovirus culture medium was ultracentrifuged to 
concentrate the viral particles, p24 ELISA revealed that CHO and HeLa cells produced very low 
concentrations of viral particles (~ 5 – 20 ng/ml for CHO and ~ 5 – 30 ng/ml for HeLa, with each 
backbone respectively). This was corroborated when no p24 or Env bands were detected by Western 
blotting. On the contrary, HEK293T cells prodced high levels of PSVs (~ 1000 ng/ml with pSG3∆env and 
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~200 ng/ml with pNL4.3-R-E-luc+) with clear Env bands on the Western blot showing gp160 as well as 
gp120. The detection of a band corresponding to gp120 indicated that gp160 was cleaved into gp120 
and gp41 (Figure 3.11). However, the gp160 band suggested that uncleaved, precursor gp160 was also 
being incorporated. Moore, et al. 113 reported a heterogenous mixture of Env oligomers on the virion 
surface including uncleaved gp160 113.  Moreover, findings by Dubay, et al. 30 suggested that the more 
uncleaved gp160 incorporated the less infectuous the resulting virus 30. Taken together, these results 
indicate that incorporation of uncleaved Env will have an impact on viral infectivity.  
Although there was no difference in the levels of cell-associated Env when HEK293T cells were co-
transfected with pSG3∆env and pNL4.3-R-E-luc+ (Figure 3.8), incorporation of pNL4.3-R-E-luc+_CAP210 
E8 was more robust than pSG3∆env_CAP210 E8 (Figure 3.11). pNL4.3-R-E-luc+ differs from pSG3∆env 
not only in the presence of the luciferase gene, but also that pNL4.3-R-E-luc+ does not express 
functional Nef and Vpr proteins 114. Nef has multiple functions which include trafficking of proteins 
and stabilising interactions between gp120 and gp41, affecting the conformation of Env – mechanisms 
suggested to influence HIV-1 infectivity 115. It is thus possible that the lack of Nef expression resulted 
in better trafficking of pSG3∆env_CAP210 E8 to the plasma membrane and/or stabilising Env 
conformations that enhanced incorporation into PSVs compared to that of pNL4.3-R-E-luc+. 
Even though HeLa cells expressed pSG3∆env_CAP210 E8 and pNL4.3-R-E-luc+_CAP210 E8 (Figure 3.8) 
there was no detectable virus-associated Env (Figure 3.11). This could be due to the very low levels of 
expression of Env in conjunction with the poor production of PSV by this cell line.  HeLa cells did also 
have the lowest transfection efficiency (Figure 3.7). pSG3∆env_CAP210 E8 and pNL4.3-R-E-
luc+_CAP210 E8 were not detected after transfection of CHO cells and this corresponded to the lack 
of virus-associated Env.  Overall this data suggests that incorporation of functional Env is dependent 
on the producer cell as well as the PSV backbone.  
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 3.2.2.8.2.2 Incorporation of Env into infectious molecular clones 
Results obtained for the incorporation of Env into IMCs were largely inconclusive considering that a 
band corresponding to p24 was only observed for pNL4.3_CAP210 E8 when IMCs were produced in 
HeLa and HEK293T cells. This suggested that either cells were not producing sufficient infectious virus 
for detection, virus was lost during ultracentrifugation and/or experimental error affected Western 
blotting. It seems likely that the latter was responsible considering that Env was detected in only HeLa-
derived IMCs, and in one instance, in the absence of p24. Although p24 was not detected, the 
Figure 3.11: Incorporation of Env into virus particles. A) HEK293T, HeLa and CHO cells were co-transfected with CAP210 
E8 and either pSG3∆env or pNL4.3-R-E-luc
+
. Cells were lysed and the maximum capacity of the well was loaded as we 
were unable to determine p24 concentrations. The PSV culture medium was harvested and ultracentrifuged for analysis 
of virion incorporation. The Western blot is a representative of two biological repeats. The blots were probed with sheep-
anti-gp120 antiserum and rabbit-anti-p24 primary antibodies. Gp160 and gp120 bands were detected with a MW of 164 
and 154 kDa, respectively. B) The cells were lysed for densitometric analysis. The values above represent the relative 
expression of Env normalized to β-actin and transfection efficiencies. 
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prominent band corresponding to gp120 for HeLa cell-derived Q23_CAP210 E8 suggested that there 
was a high level of fully processed, functional Env incorporated into these virions.  
 
 
 
 
 
  
 
 
 
 
 
 3.2.2.9 Processing: N-glycosylation 
Env expression and processing is highly dependent on the cleavage of the Env signal peptide (Env-SP) 
in the endoplasmic reticulum (ER). The inherent slow cleavage of the Env signal peptide is essential 
for the correct folding, and thus, functions of Env. Experiments that included changes in the Env-SP 
found that increased expression led to changes in Env cleavage, incorporation, viral infectivity and 
aberrant Env N-glycosylation, supporting the link between expression and Env processing 82,116. Next, 
we determined whether CAP210 E8 was differentially N-glycosylated. 
 3.2.2.9.1  Differences in N-glycosylation between cell types 
Given that N-glycosylation is dependent on the host cell machinery, we hypothesised that Env would 
have differential glycosylation patterns if expressed in different cell lines. Furthermore, differences in 
the MW of recombinant CAP210 E8 and Du151a expressed in CHO, HeLa and HEK293T cells suggested 
that Env was differentially N-glycosylated (Table 3.2). The soluble Env construct, gp140, was used to 
determine the percentage of high mannose associated with Env by digestion with endoglycosidases. 
Truncated gp160 lacking the cytoplasmic tail or transmembrane domain such as gp140 is a common 
method of expressing Env 117,118. 
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Env treated with Endo H would be stripped of high mannose N-glycans, while PNGase F would lead to 
deglycosylation. The percentage high mannose was determined by comparing the difference in MW 
of untreated Env with demannosylated Env relative to the change in MW after deglycosylation. 
CAP210 E8 gp140 was 25 % and 39 % mannosylated when produced in HEK293T and CHO cells, 
respectively. Similarly, gp120 was 30% and 38% mannosylated by HEK293T and CHO cells, respectively. 
Contrary to results reported by Raska, et al. 119, there was no significant difference in the proportion 
of high mannose N-glycans between HEK293T and CHO cells. Furthermore, the level of mannosylation 
of gp140 was similar to that identified previously by Go et al, (2011) (20 – 30 %) and less than virion 
associated gp120 (56 – 79 % oligomannose) 29,55,56,120,121. 
Interestingly, we found that most of the gp140 produced in HeLa cells carried mainly high mannose 
N-glycans as treatment with Endo H deglycosylated the glycoprotein (Figure 3.13 C). A previous study 
done by Bonomelli, et al. 29 showed that N-glycan composition shifted to predominantly high mannose 
when Env expression was increased 29. HeLa cells expressed gp140 2-fold higher than HEK293T HeLa 
cells (Figure 3.5 D), suggesting that higher levels of CAP210 E8 might have led to increased 
mannosylation. It has been suggested that over expression of Env might overwhelm the cellular 
machinery so that Env accumulates in the ER and bypasses the normal processing pathway, leading to 
aberrant N-glycosylation 48. N-glycosylation is important for Env function as expression of Env in the 
presence of tunicamycin, a glycosylation inhibitor rendered the glycoprotein non-functional 88,122 123. 
Therefore, CAP210 E8 PSVs and IMCs produced in HeLa cells should not be infectious. 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: N-glycosylation in HEK293T & CHO cells. Cells were transfected with gp140, a soluble Env clone. 48 hours 
post-transfection, the culture medium was collected for binding of gp140 to lectin beads. The bound proteins were then 
digested with endoglycosidases and run on a Western blot. The graph is a representation of 3 independent experiments. 
A) Endoglycosidase digests of gp140 produced in HEK293T cells. B) Endoglycosidase digests in CHO cells. C) 
Endoglycosidase digests in HeLa cells. ‘+’ represents gp120 positive control, ‘U’ is untreated gp140 protein, ‘E’ represents 
gp140 digested with Endo H, ‘P’ represents gp140 digested with PNGase F and pcDNA was used as a negative control. D) 
Percentage high mannose of gp140 and gp120 constructs in HEK293T and CHO cells. The shift in molecular weight was 
calculated using the equation: (MW of untreated gp140 – Endo H-treated gp140) / (MW of untreated gp140 – PNGase 
F-treated gp140) x 100. Statistical analysis was performed by one-way ANOVA in Prism 5.0 but yielded no significant 
differences. 
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3.3  Discussion  
A number of studies have compared Env antigenicity and found that neutralisation varied depending 
on whether Env was cell- or virion- associated. The authors suggested that the conformation of Env 
differed depending on the expression system, which had important ramifications for immunogen 
design. This raised a number of questions regarding the most physiologically relevant expression 
system to use for the design of vaccine candidates 108,124. It has been argued that the design of an 
efficacious vaccine depends on understanding HIV transmission and a number of investigations have 
characterised the Env of transmitted founders. Unfortunately, the studies have produced conflicting 
results possibly due to variation in expression systems. In this study, we aimed to compare expression 
systems to determine whether they resulted in differences in Env expression, cleavage, incorporation 
and N-glycosylation. 
When CAP210 E8 was expressed in different cell lines, expression levels were very similar. CHO cells, 
on the other hand, expressed and cleaved higher levels of Du151a gp160 than the other cell lines. 
These differences suggest that cell-specific host factors interact with some Envs better than others 
leading to better expression and/or processing. There was no difference in expression of gp140 and 
gp160 within cell lines, suggesting that truncation of gp41 did not influence expression. However, loss 
of the cytoplasmic tail changes Env conformation 125 so that gp140 was no longer recognised by the 
antibody used in Western blotting.  However, as we used a polyclonal anti-gp120 serum the effect of 
antibody affinity was limited.  
The MW of recombinant CAP210 E8 gp140 varied according to cell line (ranged from 189 – 151 kDa) 
but was only marginally differentially mannosylated (HEK293T and CHO cells generated gp140 with 25 
% and 39 % mannosylation, respectively and gp120 with 30 % and 38 % mannosylation, respectively). 
It is possible that the changes in mannosylation might not be the only reason for the variation in MW. 
Different levels of sialylation and/or fucosylation of complex N-glycans can also affect the apparent 
MW of glycoproteins 126. Finally, the method we used for detecting mannosylation might not be 
sensitive enough to detect small changes in N-glycosylation and mass spectrometry would have been 
a better option. However, in our laboratory bulk purification of Env was unsuccessful, preventing 
analysis by mass spectrometry (unpublished data). 
It was suggested that poor Env cleavage might contribute to differences in antigenicity (i.e. Env 
conformation) between cell-associated recombinant Env and virion-associated Env 108,109. We did not 
observe consistent cleavage of CAP210 E8 across all independent experiments and` this was likely due 
to poor expression and cleavage by all cell lines. It has been shown that recombinant Env introduced 
into mammalian cells by transfection are very poorly expressed and cleaved 106,109. However, CHO cells 
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cleaved CAP210 E8 gp160 and Du151a gp160 better than the other two cell lines, potentially due to 
the expression of a number of proteases that cleave Env 107,110. We could not reach any conclusions 
regarding the comparative cleavage efficiency of CAP210 E8 and Du151a due to the limited number 
of experiments showing consistent cleavage of both clones. However, cleavage of Du151a was 
consistently observed across all experiments. Provine, et al. 12 showed that cleavage of Env varied 
according to clone 12, suggesting that Du151a is more susceptible to cleavage by furin (or other 
proteases) than CAP210 E8. However, because of low Env expression levels, we might have 
underestimated cleavage efficiency, especially noting that we did not have multiple biological repeats. 
Expression of recombinant Env might not mimic that of in vivo expression. When we tested cell-
associated Env levels during production of PSVs and IMCs there was no difference in expression of Env 
in the presence of either PSV backbone. However, HEK293T cells expressed much higher levels of PSV-
associated Env than the other cells suggesting that HEK293T cells are better producers of PSVs. The 
presence of PSV backbones reduced Env expression levels relative to Env expressed on its own. In fact, 
CHO cells lost the ability to express detectable levels of CAP210 E8 gp160. This would then suggest 
that cell type and the presence of viral proteins affect Env expression. 
When expression was tested in the presence of IMC backbones, CHO cells only expressed a weak band 
corresponding to Env Q23_CAP210 E8. HEK293T and HeLa cells on the other hand, expressed Envs to 
varying levels depending on the IMC backbone. HeLa cells expressed pNL4.3_CAP210 E8 to much 
higher levels than matched Q23 IMCs, and HEK293T cells expressed Q23_CAP210 E8 more efficiently. 
The difference in expression of Env in the presence of PSV and IMC backbones could be due to 
interactions with other viral proteins such as Gag-gp41 interactions that influence Env concentration 
at the cell surface 125.  
Incorporation of Env into viral particles should be proportional to expression 127. We could not detect 
Env in PSVs generated in CHO and HeLa cells and this could be due to poor expression. These cell lines 
produced PSV with very low titres, as measured by p24 ELISA, suggesting that the concentration of 
PSV was too low to detect Env incorporation. HeLa and CHO cells might produce factors that interfere 
with virus production 128. When we tested HEK293T cells, we found that both gp160 and gp120 had 
been incorporated and this was consistent with the expression of pNL4.3-R-E-luc+_CAP210 E8 and 
pSG3∆env_CAP210 E8. Similar to another study, despite poor cleavage by HEK293T cells, high levels 
of CAP210 E8 gp120 was incorporated into PSVs. Herrera et al, suggested that this could be due to 
preferential uptake of gp120 124. Therefore, despite poor cleavage in HEK293T cells, high levels of 
CAP210 E8 gp120 might have been incorporated due to preferential uptake of gp120 by PSVs. 
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There were higher levels of pNL4.3-R-E-luc+_CAP210 E8 incorporated into PSVs than 
pSG3∆env_CAP210 E8. pNL4.3-R-E-luc+ differs from pSG3∆env not only in the presence of the 
luciferase gene, but also that pNL4.3-R-E-luc+ does not express functional Nef and Vpr 114. Nef has 
multiple functions which include trafficking of proteins and stabilising interactions between gp120 and 
gp41, affecting the conformation of Env – mechanisms suggested to influences HIV-1 infectivity 115. It 
is thus possible that the lack of Nef expression resulted in better trafficking of pNL4.3-R-E-luc+_CAP210 
E8 to the plasma membrane and/or stabilising Env conformations that enhance incorporation into 
PSVs. 
Incorporation of Env into IMCs was inconclusive, most likely due to very poor viral titres in conjunction 
with experimental errors and these experiments must be repeated. CHO cells expressed high levels of 
recombinant Env, but could not produce detectable IMCs and PSVs, consistent with the absence of 
cell-associated Env. Therefore, CHO cells are apparently not good producers of PSVs or IMCs but 
produce recombinant Env at high levels, with efficient cleavage. This is supported by analysis of 
literature where papers do not report on using CHO cells for PSV and IMC production while it is one 
of the few cell lines licenced to produce recombinant protein vaccines 129. Furthermore, it has been 
reported that CHO blocks infection of vaccinia virus and semlike virus, suggesting that it may not 
support expression of virus in general, including HIV 128,130. 
In conclusion, recombinant Env expression only differed between clones and not cell types, but the 
introduction of PSV and IMC backbones seemed to reduce expression and the extent of the decrease 
was determined by cell type. CHO cells expressed high levels of recombinant protein but were very 
weak producers of IMCs and PSVs, clearly indicating that some cells are not suitable to generate 
infectious viral particles. HEK293T cells seemed to be the better producer of PSVs than the other two 
cell lines and this was congruent with good Env incorporation. Overall, there was no clear pattern 
between expression systems (recombinant Env, PSVs and IMCs) and Env expression, cleavage, 
incorporation and N-glycosylation. However, the overarching outcome of this project is that the 
current methods used to study and produce Env are highly sensitive to cell type and backbone 
variation which makes it very difficult to compare the phenotype of different Env clones within and 
between studies. 
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Chapter 4 
Comparing the function of Envelope using pseudovirion single round infection and 
infectious molecular clone replication assays 
4.1  Introduction 
As discussed in Chapter 1, studies aimed at characterising TF Env have generated mixed results 10-
12,59,83,131. We hypothesised that the variation might be due to differences in study design, such as 
comparing PSV Env entry to IMC replication. It was shown previously that the antigenicity of Env varied 
when PSVs and IMCs were compared, suggesting that the methods used by different studies impact 
Env conformation and therefore function 10,12. The objective of this chapter was to determine whether 
entry efficiency of PSVs and replication of matched chimeric IMCs, generated using the same Env, 
were similar when produced by different cell lines. 
HIV-1 has high genetic diversity with nine subtypes and a number of circulating recombinants 
(Woodman and Williamson, 2009). It stands to reason that replication competent HIV requires the co-
evolution of both structural and accessory genes to maintain functional interactions. If diversification 
of Env must coincide with concomitant evolution of the entire genome to maintain viral fitness, then 
the use of primary isolates should be the best method to evaluate viral phenotype and pathogenesis 
of circulating strains. However, the culture of primary isolates has the disadvantage of poor replication 
and rapid adaptation to laboratory conditions, influencing studies comparing the fitness of circulating 
strains 132.  
Studies on Env function usually use purified recombinant protein, PSV and/or IMCs with the latter two 
approaches using standardised, HIV genomes with high replication capacity. The use of standardised 
backbones potentially reduces variation when comparing different Env variants. For example, Tat’s 
influence on viral entry will be constant for all PSVs 133, however, when comparing different Env clones, 
backbone-derived protein might interact with Env differently due to differences in Env sequence. It 
was shown that PSVs derived from the same backbone, pNL4.3-R-E-luc+- pseudotyped with two 
different Envs, had different entry efficiency 134. This could indicate intrinsic variation in function of 
the two Envs or the impact of backbone-derived proteins on Env processing, incorporation etc. To 
control for this, we used two different backbones to generate PSVs and IMCs.  
The most common isolate modified for PSV and IMC production is the backbone pNL4.3, a subtype B 
full-length clone derived from the ligation of 5’ and 3’ fragments of the LAV isolate from a 
bacteriophage lambda DNA library 104. For pseudovirus assays, pNL4.3 was modified to include a 
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luciferase gene within Nef, deletion within Env and inactivation of Nef and Vpr 114. The subtype B pSG3 
backbone was the first full-length genome cloned as a single provirus and became the standardised 
backbone for PSV neutralisation antibody assays. A stop codon was introduced within Env without 
disrupting the Vpu open reading frame to form pSG3∆env 103,135. This project utilised both pNL4.3-R-
E-luc+ and pSG3∆env to analyse the entry efficiency of a subtype C Env, raising the question of whether 
subtype differences might influence the outcome of the experiments. Although a subtype C PSV 
backbone would have been preferable, at the start of this project, none were available. Furthermore, 
it has been shown that subtype C viruses replicate poorly and less efficiently than pNL4.3 136,137.  
When we compared chimeric IMC replication we used both pNL4.3 and Q23, a subtype A HIV provirus5 
to investigate the impact of incompatible subtype-subtype viral protein-protein interactions. Both 
pNL4.3 and Q23 proviruses were adapted for yeast recombination by introducing a URA3 gene within 
Env which enabled the insertion of CAP210 E8 to generate chimeric IMCs 7,138. The final backbones: 
CMV –PBS-LTR-NL4-3∆gp160 URA and pRS315-Q23_nef-HIS3_V1-V5-URA3 differed in that Q23 did 
not express a functional Nef and was controlled by the LTR and not the cytomegalovirus promoter 5. 
Although, the use of standardised HIV-1 backbones of different subtypes allowed us to determine 
whether backbones influenced the function of the same Env clone, it did not take into account the 
cell-specific influence of auxiliary proteins on Env function such as Vpu being essential to virion 
production in only some cells and not others 139. This suggests that polymorphisms in backbone-
expressed viral proteins might result in cell type specific variation in HIV replication independent of 
Env. For this reason, we used different cell lines to produce PSVs and IMCs and compared the same 
Env clone in conjunction with different backbones. Therefore, by comparing multiple factors and 
keeping confounders constant, we determined whether Env-driven entry of PSV and IMC replication 
was influenced by cell type (HEK293T, HeLa and CHO) or backbone (pNL4.3-R-E-luc+ vs pSG3∆env; 
pNL4.3 vs Q23). 
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4.2 Results 
 4.2.1 Entry efficiency 
 4.2.1.1 Pseudovirus entry efficiency of TZM-bl cells  
To investigate the effect of producer cell line and PSV backbone, TZM-bl cells were infected with virus 
pseudotyped with two Env clones. The entry efficiency of PSVs produced in HeLa and CHOs was equal 
to the vector only control when generated with both backbones (data not shown), suggesting that 
these cells were poor producers of PSVs with CHO and HeLa cells producing concentrations of ~ 5 – 20 
ng/ml and ~ 5 – 30 ng/ml, respectively even after concentration by ultracentrifugation. 
 
 
 
 
 
 
  
 
 
 
 
 
HEK293T cells produced high concentrations of pSG3∆env_CAP210 E8 PSVs which were able to enter 
TZM-bls with approximately 8-fold higher entry efficiency compared to the vector only control (Figure 
4.1). PSVs of pNL4.3-R-E-luc+_CAP210 E8 had approximately 2.5-fold lower entry efficiency than those 
produced with the pSG3∆env backbone (Figure 4.1). The pSG3∆env backbone is thus better suited for 
the production of PSVs than pNL4.3-R-E-luc+. The lack of statistical significant difference between 
pSG3∆env_CAP210 E8 and pNL4.3-R-E-luc+_CAP210 E8 entry efficiency was likely due to the high 
variation between biological repeats. However, the apparent difference in entry efficiency of pNL4.3-
R-E-luc+_CAP210 E8 and pSG3∆env_CAP210 E8 suggests that backbone differences impacted the 
Figure 4.1: Relative entry efficiency of PSVs produced in different cell types with different PSV backbones. pNL4.3-R-
E-luc
+ 
and pSG3∆env were pseudotyped with CAP210 E8 or pCDNA3.1 plasmid (vector only control) in HEK293T cells. PSV 
titre was normalised to 100ng/ml of p24 before infection of TZM-bl cells. Entry of CAP210 E8 PSVs and vector only control 
was measured via luminescence and normalised to the entry of pSG3∆env_CAP210 E8 produced in HEK293T cells to 
reduce error between biological repeats. Entry efficiency assays were done in duplicate and bar graphs represent the 
average of two independent experiments with error bars indicating standard deviation. One-way ANOVA analysis was 
carried out using Prism 5.0 but there was no significant difference: p>0.05 
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fitness of CAP210 E8. Overall, our results suggest that PSVs generated by different cells using different 
backbones are not comparable between studies. 
 4.2.1.2  Chimeric IMC infection of TZM-bl cells 
Q23 and pNL4.3 chimeric IMCs carrying CAP210 E8 were generated by transfection of HEK293T, HeLa 
and CHO cell lines to compare IMC backbone and producer-cell effects on the ability of Env to mediate 
entry of TZM-bl cells. After 48 hours, viruses were harvested and quantified by p24 ELISA. However, 
all samples yielded very low or no p24 values. Thus, all samples were expanded in PBMCs to increase 
viral titre and subsequently used to infect TZM-bl cells. The deviation from our original protocol limited 
the extent of our analysis because expansion in PBMCs would likely abrogate all cell-specific effects 
achieved by transfection of different cell lines. However, to make it easier to distinguish samples we 
continued to refer to the IMCs based on their producer line.  
Surprisingly, not all IMCs were able to enter TZM-bl cells even though they were passaged through 
PBMCs. This suggested that some cell lines were not good producers of IMCs and that expansion in 
PBMCs did not make a difference. This was highlighted when CHO cells apparently did not produce 
infectious IMCs irrespective of backbone and HEK293T and HeLa cells did not produce detectable 
pNL4.3_CAP210 E8 and Q23_CAP210 E8 IMCs (Figure 4.2). It is possible that all cell lines were unable 
to produce infectious IMCs carrying CAP210 E8 or the viral titre was too low for detection by 
luminescence.  
When HEK293T and HeLa cells were transfected with the pNL4.3 provirus, the expanded IMCs infected 
TZM-bl cells similarly: approximately 5- and 7-fold, respectively, better than the cells only control 
(Figure 4.2). The similar infectivity of IMCs produced by the two cell types is likely because we are 
effectively comparing the same virus after expansion in PBMCs. As far as we know, the only difference 
between pNL4.3 provirus and pNL4.3_CAP210 E8 is the presence of different Envs. Detectable 
replication of pNL4.3 provirus and not pNL4.3_CAP210 E8 is likely due to Env-specific differences. On 
the other hand, IMC replication was also affected by backbone seeing that Q23_CAP210 E8 IMCs 
infection of TZM-bl cells was not detected probably because the viral titre was too low. Therefore, at 
this point, we can only suggest that overall, the CHO cell line is not suitable for IMC production, 
HEK293T and HeLa cells produce detectable infectious IMCs for only certain Envs and pNL4.3 might 
be a good candidate backbone to use for IMC replication in PBMCs.  
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4.2.2 Replication kinetics of infectious molecular clones 
 4.2.2.1 Identification of donor PBMCs permissive to IMC replication 
Blood from the Western Province Blood Transfusion Service was obtained from 15 donors and used 
to isolate PBMCs for IMC expansion and replication assays. As PBMCs from different donors do not 
always support HIV replication, we tested the donors used in the replication assay for the ability to 
support replication of pNL4.3 provirus generated in HEK293T cells. Viruses were first expanded in a 
mixed pool of donor PBMCs before replication in specific donor PBMCs for/+- 14 days after which p24 
concentrations were determined using an ELISA. IMCs of pNL4.3 provirus equivalent to 100 ng/ml p24 
were able to replicate in two PBMC donors (Table 4.1).  
 
Donor Donor 11 Donor 12 
Harvest day Day 4 Day 14 Day 4 Day 14 
p24 concentration (ng/ml) 62.7 75.7 56.6 75.1 
 
 
Figure 4.2: Infection of IMCs produced in different cell types with different IMC backbones. HEK293T (green), HeLa 
(pink) and CHO (blue) cells were transfected with the DNA of pNL4.3_CAP210 E8, Q23_CAP210 E8 and pNL4.3 provirus 
(AIDS Reagent Programme, NIH). TZM-bl cells were infected with IMCs after expansion in PBMCs and infection was 
measured by luminescence after 72 hours using BrightGlo (Promega). Infection was normalised to cells only control. Bars 
represent the average of two biological repeats each done in duplicate with error bars indicating standard deviation. 
Labelling is as follows: pNL4.3_CAP210 E8 is the IMC generated using the pCMV-PBS-LTR-NL4-3∆gp160/URA backbone, 
Q23_CAP210 E8 is the IMC generated with the Q23 backbone and pNL4.3 is the HIV-1 provirus which served as a positive 
control. No significant differences were found between any of the samples using the one-way ANOVA test in Prism 5.0.  
 
-2
0
2
4
6
8
10
12
p
N
L4
.3
_
C
A
P
2
1
0
 E
8
Q
2
3
_
C
A
P
2
1
0
 E
8
p
N
L4
.3
p
N
L4
.3
_
C
A
P
2
1
0
 E
8
Q
2
3
_
C
A
P
2
1
0
 E
8
p
N
L4
.3
p
N
L4
.3
_
C
A
P
2
1
0
 E
8
Q
2
3
_
C
A
P
2
1
0
 E
8
p
N
L4
.3
HEK HeLa CHO
R
e
la
ti
ve
 I
M
C
 e
n
tr
y 
e
ff
ic
ie
n
cy
 (
Fo
ld
-
ch
an
ge
)
Table 4.1: Replication of pNL4.3 provirus in donor PBMCs after 14 days. 
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4.2.2.2  Determining whether Env clones influence the replication of pNL4.3_CAP210 E8 and 
pNL4.3 provirus  
As infection of TZM-bl cells was not consistently detected when inoculated with low virus 
concentration, samples were ultracentrifuged to concentrate the virus before replication in PBMCs. 
Despite expansion and ultracentrifugation, the concentration of virus was too low to determine 
TCID50 or p24 ELISA. PBMCs were thus infected with IMCs normalised to 15 x background 
luminescence obtained by infection of TZM-bl cells. As the titre of CHO-produced IMCs was lower than 
15 x background total volume of virus was used for infection of PBMCs.  
IMCs replicated for 7, 10, 14 and 17 days after which p24 concentrations were measured by ELISA. We 
first compared the impact of Env clones (pNL4.3 and CAP210 E8) on the replication of pNL4.3 IMCs. 
Figure 4.3 shows that the replication of the IMCs was highly variable. However, overall, there seemed 
to be consensus as the majority of experiments (8/12) indicated that pNL4.3_CAP210 E8 replicated to 
higher titres than pNL4.3 provirus (Figure 4.3). As the IMCs were expanded in PBMCs, one would 
expect that all pNL4.3 provirus would replicate to the same level. However, 50 % of the experiments 
(6/12) indicated that pNL4.3 provirus was unable to replicate in PBMCs irrespective of donor and 
biological repeat. This unexpected finding could be due to the sensitivity of these assays to 
experimental error especially noting the variation between biological repeats using the same donor.  
The results from PBMC replication experiments are contrary to the TZM-bl infection data where most 
pNL4.3 provirus were able to infect the reporter cell line (Figure 4.2). It is possible that the differences 
between these assays is because of variation in TZM-bl and PBMC host factors such as transcription 
factors that recognise the LTR enhancer sites. When we compared producer cell lines; in 3/4 
experiments HEK293T cells produced ‘non-infectious’ pNL4.3 provirus compared to CHO cells that 
produced IMCs unable to replicate in PBMCs in only one experiment. This could indicate that producer 
cells might have an effect on subsequent IMC replication in PBMCs. This is unexpected as all viruses 
were expanded in PBMCs and should no longer carry any signatures derived from their producer cell 
line. It is interesting to speculate however that epigenetic changes to the LTR in the producer cells 
lines influence replication in PBMCs 140. 
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It is possible that we can no longer directly compare the replication pNL4.3 backbone constructs 
because manipulation during plasmid construction of pCMV-PBS-LTR-NL4-3∆gp160/URA backbone for 
homologous recombination might have altered the pNL4.3 provirus. In addition, the low 
concentrations of pNL4.3_CAP210 E8 and pNL4.3 provirus IMC inoculum used in this project might 
also have influenced the outcome of the study. Overall, the results suggested that CAP210 E8-driven 
IMC replication might have higher replicative ability compared to IMCs carrying the pNL4.3 Env.  
 
Figure 4.3: Comparison of the replication of pNL4.3_CAP210 E8 and pNL4.3 provirus produced in different cell lines. 
IMCs were generated in A, D, G, J) HEK293T, B, E, H, K) HeLa and C, F, I, L) CHO cells with pNL4.3 carrying either pNL4.3 
Env (solid red line) or CAP210 E8 Env (dotted red line). PBMCs from donors 11 (A-F) and 12 (G-L) were infected with the 
maximum possible pNL4.3 provirus and pNL4.3_CAP210 E8 produced in all three cell lines for biological repeats 1 and 2. 
All viruses were normalised to 15X background based on infection of TZM-bl cells as p24 concentrations were not 
detected. IMCs produced in CHO cells were not normalised to background and total virus was used for infections.  Culture 
medium was collected on days 7, 10, 14 and 17 post-infection and viral titre quantified by p24 ELISA (ng/ml). 
pNL4.3_CAP210 E8 is a chimeric IMC made using the pCMV-PBS-LTR-NL4-3∆gp160/URA backbone. Graphs indicate data 
of biological repeat 1 using donor 11 (A, B, C) and donor 12 (G, H, I) and biological repeat 2 using donor 11 (D, E, F) and 
donor 12 (J, K, L). Biological repeat 1, day 14 values were not included due to experimental error. 
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4.2.2.3  Determining whether backbone differences influence the replication of 
pNL4.3_CAP210 E8 and Q23_CAP210 E8  
After finding that Envs seemed to impact replication of IMCs, we sought to compare the effect of 
backbones on IMC replication. We transfected HEK293T, HeLa and CHO cells with pNL4.3_CAP210 E8 
and Q23_CAP210 E8, harvested the virus, ultracentrifuged and expanded in PBMCs. After 17 days of 
expansion, the viruses were ultracentrifuged again and then used to infect PBMC donors 11 and 12 in 
two independent experiments. There seemed to be a trend where 7/12 experiments indicated that 
Q23_CAP210 E8 were able to replicate to higher titres than pNL4.3_CAP210 E8 (Figure 4.4) (Table 4.1). 
However, there was a high level of variation which might have influenced the findings. High variation 
in donor PBMCs has been reported 141. To make definitive conclusions regarding the effect of 
backbone on replicative fitness, these experiments need to be repeated.  
 
  Biological Repeat 1 Biological Repeat 2 
  Donor 11 Donor 12 Donor 11 Donor 12 
HEK293T  Q23_CAP210 < 
pNL4.3_CAP210 
Q23_CAP210 < 
pNL4.3_CAP210 
Q23_CAP210 > 
pNL4.3_CAP210 
Q23_CAP210 > 
pNL4.3_CAP210 
HeLa Q23_CAP210 > 
pNL4.3_CAP210 
Q23_CAP210 > 
pNL4.3_CAP210 
Q23_CAP210 > 
pNL4.3_CAP210 
Q23_CAP210 < 
pNL4.3_CAP210 
CHO Q23_CAP210 < 
pNL4.3_CAP210 
Q23_CAP210 < 
pNL4.3_CAP210 
Q23_CAP210 > 
pNL4.3_CAP210 
Q23_CAP210 > 
pNL4.3_CAP210 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 Rank order of Q23 and pNL4.1 replicative fitness according to cell line used to produce IMCs 
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4.4 Discussion 
Considering that many HIV studies employ the PSV and IMC systems for determining Env function, it 
is reasonable to question whether using different backbones and cell types influence study outcomes. 
The results obtained in this study suggest that expression systems and backbone identity do influence 
the ability of the virus to enter cells.  
Firstly, we must acknowledge the variation we observed between biological repeats using the same 
constructs and donor PBMCs. Here we see that even using the same donor, the assay is highly 
susceptible to variation. We plan to do more biological repeats using the same donor PBMCs and 
taking into account the titre of the infecting IMCs as this was likely the biggest confounding factor of 
Figure 4.4: Comparison of the replication of pNL4.3_CAP210 E8 and Q23_CAP210 E8 produced in different cell lines. 
pNL4.3_CAP210 E8 (red lines) and Q23_CAP210 E8 (black lines) IMCs were generated in HEK293T (dotted line), HeLa 
(dashed line) and CHO (solid line) cells. A) Donor 11 and B) donor 12 PBMCs, were infected with either IMC equivalent to 
15X background luminescence or the total volume of virus obtained after ultracentrifugation as we did not obtain p24 
concentrations. Virus supernatants were collected on days 7, 10, 14 and 17 post-infection and quantified by p24 ELISA 
(ng/ml). pNL4.3_CAP210 E8 is a chimeric IMC made by inserting subtype C CAP210 E8 into the pCMV-PBS-LTR-NL4-
3∆gp160/URA 5 backbone and Q23-CAP210 E8 was generated by inserting subtype C CAP210 E8 into pRS315-Q23_nef-
HIS3_V1-V5-URA3 7. Data represents biological repeat 1 (A and B) and 2 (C and D). 
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this study.  Secondly, the intention of these experiments was to compare IMCs that came directly from 
HEK293T, HeLa and CHO cells. However, due to the low titres obtained after the initial transfection of 
these cell lines, the viruses were expanded in PBMCs prior to investigating their replication. This means 
that the effect of cell type on IMC production may have been lost after multiple rounds of passage 
through PBMCs. Therefore, to make proper comparisons of cell type effect on IMCs, we will have to 
repeat these experiments without expansion in PMBCs. 
Despite this consideration, we compared 1) the entry efficiency of PSVs generated by the different cell 
lines and 2) the ability of IMCs generated by different backbones and carrying different Envs to infect 
TZM-bl cells and replicate in PBMCs.  
When PSVs were generated with pSG3∆env and pNL4.3-R-E-luc+, only HEK293T cells were able to 
produce virions that infected TZM-bl cells, whereas PSVs produced in HeLa and CHO cells were not 
detected using the reporter cell line. During production of PSVs Env was expressed best in HEK293T 
cells, weakly in HeLa cells and apparently, not at all by CHO cells. As HeLa cells expressed Env we were 
surprised that PSVs could not infect TZM-bl cells. HeLa cells and CHO cells have been shown to produce 
tetherin which prevents the release of viral particles at the cell membrane 142,143. On the other hand, 
HEK293T cells do not produce tetherin 144. It is thus possible that HeLa and CHO cells are unable to 
release high levels of PSV due the expression of tetherin. However, pSG3∆env and pNL4.3E-R-luc+ 
express Vpu, which counters the effect of tetherin. 
It is the expression of Vpu that enables PBMCs to support HIV infection. 145. In order for tetherin to 
prevent the release of HIV, it must be trafficked to the plasma membrane. At the cell surface, it binds 
virus and inhibits release. Vpu reduces tetherin levels at the cell surface by sequestering tetherin in 
the trans golgi network 87. A functional Vpu was expressed by all PSV and IMC backbones used in this 
project. Therefore, IMCs of pNL4.3 provirus, pNL4.3_CAP210 E8 and Q23_CAP210 E8 were able to 
replicate in PBMCs due to the presence of a functional Vpu, albeit inconsistently with pNL4.3_CAP210 
E8 unable to replicate to detectable levels in some experiments and then outgrowing pNL4.3_CAP210 
E8 in others. 
The lack of consistency between experiments could be due to a number of factors. When IMCs were 
produced in HeLa and CHO cells, tetherin might have reduced the amount of virus released so that 
less virus was added to the TZM-bl cells and PBMCs. The titre of IMCs was probably too low to induce 
a detectable luciferase signal after 72 hours infection of TZM-bl cells but that repeated cycles of 
replication in PBMCs increased virus concentration sufficient for detection by p24 ELISA. However, the 
low concentration of the inoculum would have affected how rapidly the virus was able to replicate in 
PBMCs to a detectable level. This would explain why IMCs produced by CHO cells were able to 1) 
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replicate in PBMCs 2) but were unable to enter TZM-bl cells and 3) did not produce detectable levels 
of PSVs.  
Another confounding factor that might have influenced direct comparison between pNL4.3 Env and 
CAP210 E8 and the ability of IMCs to mediate entry of TZM-bl cells and PBMCs is that CAP210 E8 is R5- 
and pNL4.3 is X4-tropic. However, TZM-bl cells, derived from HeLa cells also express endogenous 
CXCR4 co-receptor, similar to PBMCs so it is highly unlikely that tropism affected the study outcome 
146. However, comparing Envs with the same tropism expressed by the same backbone would have 
helped limit confounding factors. There might also have been other factors that played a role in the 
variation in our findings, noting the low expression of Env by some cell lines discussed in chapter 3. 
Finally, the variation between experiments was also affected by experimental error worsened the 
poor virus production.  
Results from the study conducted by Ndung'u et al. (2001) suggested that a subtype C IMC replicated 
significantly less efficiently than a subtype B IMC, pSVIII/89.6. When considering the results obtained 
for the replication assay in our study, it is possible that the subtype used to generate IMCs might have 
played a role in the production of the virus. Q23_CAP210 E8, the subtype A backbone, apparently did 
not produce IMCs able to infect TZM-bls, similar to pNL4.3_CAP210 E8, the subtype B backbone. 
However, comparisons between Q23_CAP210 E8 and pNL4.3_CAP210 E8 IMC replication in PBMCs 
suggested that Q23 was more compatible with CAP210 E8 than pNL4.3 as it replicated more often to 
higher titres. However, the high variation between backbones and donors as well as between 
biological repeats suggests that more than one factor influenced the ability of CAP210 E8 to mediate 
infection of the IMCs. 
Overall, this data suggests that the selection of cell lines to produce PSVs and IMCs are crucial to the 
outcome of experiments looking at entry of a reporter cell line such as TZM-bl cells and that 
comparison of Env phenotype should be done using a compatible backbone. Therefore, comparison 
of Env function is most likely best achieved through replication of chimeric IMCs, generated using the 
same backbone, in PBMCs isolated from a number of donors to reduce the effect of donor variability. 
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Chapter 5 
Conclusion 
5.1 Introduction 
Previous studies conducted by Louder, et al. 10 and Provine, et al. 12 presented conflicting results 
regarding the characteristics of PSVs and IMCs. Their findings were important as a number of studies 
utilised either PSVs or IMCs to characterise HIV transmission. We therefore compared the effect of 
producer cell type, HIV backbone, and Env clone on the entry and replication of PSVs and IMCs and 
whether any variation could be explained by differences in Env expression, cleavage, incorporation 
and N-glycosylation. In this chapter we will provide an overview of our data to highlight the 
importance of standardising methods across laboratories, especially when identifying characteristics 
of TF for vaccine development. The data shown in the tables below were derived from graphs in 
chapters 3 and 4 and in order to compare the data, positive controls or background controls were 
used as references to generate relative values depicted as either + (weak), ++ (moderate) or +++ 
(strong).  
5.2 Comparison of Env expression and incorporation, with PSV entry and IMC replication  
 
Cell type 
PSV Env 
expression 
IMC Env 
expression 
PSV Env 
incorporation 
IMC Env 
incorporation 
PSV entry *IMC entry 
#*IMC 
replication 
HEK293T +++ ++ + - +++ - +++ 
HeLa + +++ - ++ - - ++ 
CHO - - - - - - +++ 
* This was based on IMC expanded in PBMCs. 
# Average relative to pNL4.3 provirus replication shown in Figure 4.3. Rough analysis: CAP210 E8 = pNL4.3: ++; CAP210 E8 > 
pNL4.3: +++; CAP210 E8 < pNL4.3: + 
In Table 5.1 PSV entry appeared to be host cell-specific as the HEK293T cell line were the only cells 
that produced PSVs able to infect TZM-bl cells. This coincided with expression and incorporation of 
Env into PSVs; HeLa and CHO cells did not generate PSVs with detectable levels of Env. CAP210 E8 
gp140 was highly mannosylated by HeLa cells and we hypothesised that PSVs produced by these cells 
would be non-infectious. It has also been shown that incorporation of Env is cell type-dependent 
because of host cell factors interacting with the cytoplasmic tail of gp41 127. Our experiments 
corroborate these findings and suggest that HEK293T cells might express factors that enhance Env 
incorporation into PSVs resulting in higher entry of TZM-bl cells compared to other cell lines. As 
Table 5.1: Summary of characteristics of matched CAP210E8 pseudovirus and chimeric infectious molecular clone 
generated with the pNL4.3 backbone 
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discussed before, HeLa and CHO cells might also produce tetherin which might have influenced release 
of HIV, affecting viral titre. 
Contrary to PSV entry data, HEK293T cells did not produce IMCs able to infect TZM-bl cells. This was 
an unexpected result as HEK293T cells are routinely used for IMC production and it is likely that 
experimental error led to very low levels of virus production rather than non-infectious IMCs. After 
transfection of all cell lines, p24 ELISA did not detect CAP210 E8 IMCs and we thus expanded the IMCs 
in PBMCs which were then normalised based on luciferase readings in TZM-bl cells. We isolated too 
little virus to calculate p24 levels or TCID50 and it is possible that we miscalculated the titre which 
ultimately affected the TZM-bl entry and IMC replication assays. As the IMCs were passaged through 
PBMCs we could not directly compare the effect of producer cells on IMC entry with that of PSV entry.  
To measure IMC replication, expanded virus was ultracentrifuged, normalised to TZM-bl luciferase 
readings and used to infect PBMCs.  Contrary to the TZM-bl entry data, we detected replication with 
IMCs produced in all cell lines with those originally generated in HEK293T and CHO cells being better 
producers of infectious virus than HeLa cells. However, this difference is also likely due to experimental 
error as any cell-specific effect of producer cells on Env function and/or processing and IMC replication 
would have been lost during expansion in PBMCs. Louder, et al. 10 found that passaging IMCs through 
HEK293T cells altered neutralisation sensitivity10, supporting that expression in PBMCs resulted in Env 
with altered conformation. Therefore, irrespective of what cell produced the IMC, after passage in 
PBMCs, they were ostensibly identical viruses. PSVs on the other hand might still be influenced by host 
cell-specific processing. 
5.3 Comparison of expression, incorporation and entry of PSVs produced by two backbones 
 
Cell type HEK293T HeLa CHO 
Backbone Expression Incorporation Entry Expression Incorporation Entry Expression  Incorporation Entry 
pSG3 * ++ + +++ + - - - - - 
pNL4.3 
R.E-luc+ * 
++ + ++ + - - - - - 
* PSVs were produced with CAP210E8 
When comparing the overall results for PSVs, we see a cell type-dependent effect. HEK293T cells 
expressed detectable Env in the presence of both backbones which corresponded to entry into TZM-
bl cells. Although HeLa cells were able to express low levels of Env in the presence of both backbones, 
the expression did not seem to result in incorporation and entry of PSVs. PSVs produced in CHO cells 
were unable to enter TZM-bl cells and this corresponded to lack of Env expression and incorporation. 
Table 5.2: Summary of the effect of pSG3DEnv and pNL4.3R-E-luc+ backbones on pseudovirus produced in HEK293T, HeLa and 
CHO cells. 
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Backbones, pSG3Δenv and pNL4.3R-E-luc+ did not have an effect on PSV production suggesting that 
viral protein-Env interactions were not important in this assay.  
5.4 Comparison of Env expression, incorporation and replication of infectious molecular clones 
generated by two backbones 
Unlike in the case of PSVs, when we compared the effect of Q23 and pNL4.3 on Env expression and 
incorporation and IMC replication, the results were not consistent between backbones (Table 5.3).  
 
 
Cell type HEK293T HeLa CHO 
Backbone Expression Incorporation *Replication Expression Incorporation *Replication Expression Incorporation *Replication 
Q23 +++ - +++ + + + - - +++ 
pNL4.3 + - - +++ +++ + - - ++ 
*Replication of IMCs relative to one another 
Although, producer cell should not affect IMC replication after passage in PBMCs, there seemed to be 
some association. The lack of Env incorporation and replication of IMCs produced by HEK293T cells 
was likely due to experimental error as HEK293T cells are common producers of infectious virus in the 
literature. CHO cells, however, seemed to consistently demonstrate poor Env expression and 
incorporation which suggests that these cells do not produce high titres of HIV. It has been shown that 
CHO cells appear to be resistant to virus infection and this might have influenced our ability to detect 
Env.  
The experimental error and possible resistance of CHO cells to produce virus to high titres influenced 
our ability to confirm whether pNL4.3 or Q23 were better at generating replication competent IMCs. 
In most experiments, CHO cell-derived IMCs were not normalised to 15 x background due to poor 
titre. However, this did not seem to affect the replication of these IMCs as many out-replicated the 
other variants. Overall, Q23_CAP210 E8 performed better in most replication experiments suggesting 
that there could be backbone-dependent effects on IMCs. We saw similar results when we compared 
PSV backbones, with pSG3env PSVs better able to infect TZM-bl cells. Therefore, comparison 
between matched PSV and chimeric IMC phenotype should be done in the same backbone to limit 
variation between experiments.  
In the study conducted by Provine, et al. 12, significant differences were found between matched pairs 
of PSVs and IMCs. The authors suggest that the differences found between these two systems cannot 
Table 5.3: Summary of the effect of pNL4.3 and Q23 backbones on the production of CAP210 E8 chimeric infectious molecular clones passaged 
in PBMCs 
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be attributed to differential cleavage nor incorporation alone. Within the context of the earlier study, 
our findings suggest that each of the factors investigated herein had some impact on the resulting 
viruses, whether PSV- or IMC-derived. Experiments of IMC replication and incorporation must be 
repeated to obtain higher viral titre to circumvent expansion of virus in PBMCs. Overall, we can 
conclude that both PSV and IMC assays are very sensitive to variation and numerous biological repeats 
need to be performed for reproducible results. Furthermore, before direct comparison between 
studies that have used IMCs and PSVs, we must take into account the variation between the assays 
and that even repetition with the same cells and matched backbones might not yield the same results 
when comparing different Envs. The research community must standardize methods of characterising 
Envs in order to best understand its function and pathogenesis of HIV.  
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Q23CAP210E8 ....................................................................................................
2510 2520 2530 2540 2550 2560 2570 2580 2590
... .|... .|. ... |. ...|.. ..| ... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. .
CAP210_E8 CAACAGATAGAATTTTAGAATTACTACAAAGGATTTGGAGAGGTATCTGCAACGTACCTACAAGAATAAGACAGGGCTTTGAAGCAGCTTTGCAATAA
Q23CAP210E8 ..................................................................................................
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Figure A1: Full sequence alignment of chimeric IMC, Q23_CAP210 E8 to CAP210 E8. E. coli was transformed with 
chimeric IMC DNA. Positive colonies were selected and sent for sequencing. The alignment above shows that the CAP210 
E8 Env was successfully inserted into the Q23 vector.  
CAP210_E8 CAGCATCCATAACGCTGACGGTACAAGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAAAGTAATTTGCTGAGAGCTATAGAGGCGCAACAACATAT
Q23CAP210E8 ....................................................................................................
1710 1720 1730 1740 1750 1760 1770 1780 1790 1800
... .| ... .|. ...|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 GTTGCAACTCACAGTCTGGGGCATTAAGCAGCTTCAGACAAGAGTCCTGGCTATAGAAAGATACCTAAAGGATCAACAGCTCCTAGGGATTTGGGGATGC
Q23CAP210E8 ....................................................................................................
1810 1820 1830 1840 1850 1860 1870 1880 1890 1900
... .| ... .|. ...|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 TCTGGAAAACTCATCTGCACCACTAATGTGCCTTGGAACTCTAGTTGGAGTAACAAATCTTATGGGGACATTTGGGATAACATGACCTGGATGCAGTGGG
Q23CAP210E8 ....................................................................................................
1910 1920 1930 1940 1950 1960 1970 1980 1990 2000
... .| ... .|. ...|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 ATAGAGAAATTAATAACTACACAAACACAATATACAGGTTGCTTGAAGACTCGCAAAACCAGCAGGAAAAAAATGAACAAGATTTATTAGCATTGGACAA
Q23CAP210E8 ....................................................................................................
2010 2020 2030 2040 2050 2060 2070 2080 2090 2100
... .| ... .|. ...|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 ATGGCAAAGTCTGTGGTCGTGGTTTAGTATATCAAGCTGGCTATGGTATATAAAAATATTCATAATGGTAGTAGGAGGATTGATAGGTTTAAGAATAATT
Q23CAP210E8 ....................................................................................................
2110 2120 2130 2140 2150 2160 2170 2180 2190 2200
... .|... .|....|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 TTTGCTGTGCTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCCTTATCGTTGCAGACCCTCCCCCCAAACCCGAGGGAACTCGACAGGCTCGGAG
Q23CAP210E8 ....................................................................................................
2210 2220 2230 2240 2250 2260 2270 2280 2290 2300
... .|... .|....|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 GAATCGAAGAAGAAGGTGGAGAGCAAGACAGAGGCAGATCTGTGAGATTAGTGAGCGGATTCTTACCACTTGCCTGGGACGATCTGAGGAGCCTGTGCCT
Q23CAP210E8 ....................................................................................................
2310 2320 2330 2340 2350 2360 2370 2380 2390 2400
... .|... .|....|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 CTTCTGCTACCACCGATTGAGAGACTTACTATTGATCACAACGAGAGCGGTGGAACTTCTGGCACGCAGCATTCTCAAGGGACTACAGAGGGGGTGGGAA
Q23CAP210E8 ....................................................................................................
2410 2420 2430 2440 2450 2460 2470 2480 2490 2500
... .|... .|....|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. ..|
CAP210_E8 ATCCTTAAATATCTGGGAAGTCTTGTGCAGTATTGGGGTCAGGAGCTAAAAAAGAGTGCTATTAATCTGCTTGATACCACAGCAATAGCAGTAGCTGAGG
Q23CAP210E8 ....................................................................................................
2510 2520 2530 2540 2550 2560 2570 2580 2590
... .|... .|....|. ...|.. ..|... .| ....|. ...|. ...|.. ..|... .|....|. ...|. ...|.. ..|....| ....|. ...|. ...|.. .
CAP210_E8 CAACAGATAGAATTTTAGAATTACTACAAAGGATTTGGAGAGGTATCTGCAACGTACCTACAAGAATAAGACAGGGCTTTGAAGCAGCTTTGCAATAA
Q23CAP210E8 ..................................................................................................
